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A B S T R A C T
Background
Gastroesophageal reflux disease (GORD) is said to be the causative factor in up to 41% of adults with chronic cough. Treatment for
GORD includes conservative measures (diet manipulation), pharmaceutical therapy (motility or prokinetic agents, H2-antagonist and
proton pump inhibitors (PPI)) and fundoplication.
Objectives
To evaluate the efficacy of GORD treatment on chronic cough in children and adults with GORD and prolonged cough that is not
related to an underlying respiratory disease, i.e. non-specific chronic cough.
Search methods
We searched the Cochrane Airways Group Specialised Register, the Cochrane Register of Controlled Trials (CENTRAL), MEDLINE,
EMBASE, review articles and reference lists of relevant articles. The date of last search was 8 April 2010.
Selection criteria
All randomised controlled trials (RCTs) on GORD treatment for cough in children and adults without primary lung disease.
Data collection and analysis
Two review authors independently assessed trial quality and extracted data. We contacted study authors for further information.
Main results
We included 19 studies (six paediatric, 13 adults). None of the paediatric studies could be combined for meta-analysis. A single RCT
in infants found that PPI (compared to placebo) was not efficacious for cough outcomes (favouring placebo OR 1.61; 95% CI 0.57 to
4.55) but those on PPI had significantly increased adverse events (OR 5.56; 95% CI 1.18 to 26.25) (number needed to treat for harm
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in four weeks was 11 (95% CI 3 to 232)). In adults, analysis of H2 antagonist, motility agents and conservative treatment for GORD
was not possible (lack of data) and there were no controlled studies of fundoplication. We analysed nine adult studies comparing PPI
(two to three months) to placebo for various outcomes in the meta-analysis. Using intention-to-treat, pooled data from studies resulted
in no significant difference between treatment and placebo in total resolution of cough (OR 0.46; 95% CI 0.19 to 1.15). Pooled data
revealed no overall significant improvement in cough outcomes (end of trial or change in cough scores). We only found significant
differences in sensitivity analyses. We found a significant improvement in change of cough scores at end of intervention (two to three
months) in those receiving PPI (standardised mean difference -0.41; 95% CI -0.75 to -0.07) using generic inverse variance analysis on
cross-over trials. Two studies reported improvement in cough after five days to two weeks of treatment.
Authors’ conclusions
PPI is not efficacious for cough associated with GORD symptoms in very young children (including infants) and should not be used
for cough outcomes. There is insufficient data in older children to draw any valid conclusions. In adults, there is insufficient evidence
to conclude definitely that GORD treatment with PPI is universally beneficial for cough associated with GORD. Clinicians should
be cognisant of the period (natural resolution with time) and placebo effect in studies that utilise cough as an outcome measure.
Future paediatric and adult studies should be double-blind, randomised controlled and parallel-design, using treatments for at least two
months, with validated subjective and objective cough outcomes and include ascertainment of time to respond as well as assessment of
acid and/or non-acid reflux.
P L A I N L A N G U A G E S U M M A R Y
Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Cough in association with gastroesophageal reflux disease (GORD) is common in adults with chronic cough. The objective of this
review was to evaluate the effectiveness of GORD treatment in children and adults with GORD and prolonged cough that is not
related to an underlying respiratory disease, i.e. non-specific chronic cough.
Nineteen studies fulfilled our predetermined criteria but only six could be combined (in meta-analysis). We obtained additional data
from trialists. We were not able to combine results in children due to limited data. Thickened feeds had an inconsistent effect. Proton
pump inhibitors (PPI) did not reduce cough and should not be used for cough in young children.
In adults with cough and GORD, no significant difference was found in clinical cure using proton pump inhibitors (PPI) for cough
and GORD. Using other outcomes, there was also no significant difference between PPI and placebo. This review also highlights a
large placebo and time period effect (natural resolution with time) of treatment for chronic cough. In adults treatment with PPI for
cough associated with GORD is inconsistent and its benefit variable. There was insufficient data to draw any conclusion from other
therapies for cough associated with GORD.
B A C K G R O U N D
Cough is the most common symptom presenting to general prac-
titioners (Britt 2002). Worldwide, the desire to reduce the impact
of the symptom of cough is reflected in the billions of dollars spent
on over the counter cough and cold medications. Non-specific
cough has been defined as non-productive cough in the absence of
identifiable respiratory disease or known aetiology (Chang 2001).
Prolonged or chronic cough has been variously defined as a cough
which persists for longer than three to eight weeks.
Gastroesophageal reflux (GOR) (reflux of gastric contents into the
oesophagus) can be acid or non-acid (volume or alkaline reflux)
and these occur physiologically, especially in the post-cibal state
(AMA 1996).When reflux is ’excessive’, GOR disease (GORD) is
present. Symptoms attributed to GORD range from a variety of
gastrointestinal/abdominal symptoms (abdominal pain, halitosis,
water brash etc.) to extra-oesophageal symptoms (cough, hoarse-
ness, laryngeal problems, ear disease, dental erosion etc.) (AMA
1996). In 2006 and 2009, the definition of GORD was refined
to “a condition that develops when the reflux of stomach contents
causes troublesome symptoms and/or complications” (Vakil 2006;
2Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vandenplas 2009).
Cohort studies in adults suggest that gastroesophageal reflux dis-
ease (GORD) related to acid causes 21% to 41% of chronic non-
specific cough, even in many with no gastrointestinal symptoms
of GORD (Irwin 1990). When successfully treated, GORD-re-
lated cough is associated with a decrease in objective measure-
ments of cough sensitivity (O’Connell 1994). In animals, potent
acid instillation into the oesophagus causes airway neurogenic in-
flammation (Daoui 2002). In adult humans similar experimenta-
tion causes cough in a temporal manner (within 70 seconds) (Ing
1994). Although a temporal relationship has been shown in the
laboratory, cough is reported in some earlier studies to resolve only
after a mean time period of 169 to 179 days following treatment
for acid-GORD related cough (Irwin 2002a). It is thus not sur-
prising that conflicting data have been reported and others have
shown that acid GORD is associated with, but not the causative
factor for, cough. Also, effective treatment of GORD that resolves
gastrointestinal GORD symptoms may have no effect on objec-
tive pulmonary data (Ferrari 1995). Furthermore, like asthma and
GORD, both GORD and cough are common diseases, often co-
exist, and their association does not imply cause and effect (AMA
1996; Rudolph 2001; Vakil 2006; Vandenplas 2009). Neverthe-
less, several reviews/guidelines suggest a therapeutic trial of three
to six months of GORD treatment for non-specific chronic dry
cough in both adults and children (Corrao 1996; Irwin 2002a;
Kiljander 2003).
Current treatment for GORD includes conservative anti-reflux
measures (diet, positioning etc.), pharmacological approaches
(acid suppressing agents: histamine2 (H2) receptor antagonists,
proton pump inhibitors (PPI) and prokinetic agents: domperi-
done, erythromycin, metoclopramide and previously cisapride)
and surgical approaches (Nissen or Toupet fundoplication by la-
paroscopic or open procedures) (Rudolph 2001).
There are several definitions of GORD. Excessive distal oe-
sophageal acidification is the most common clinical scenario of
GORD and can be defined by the histological presence of reflux
oesophagitis (on biopsy) or distal oesophageal pH-metry (24-hour
pH study) (AMA 1996). Distal pH-metry is the most sensitive
method for defining acid GORD and is a standard test recom-
mended for evaluating chronic cough (Chung 1996; Irwin 1998).
In children, acid GORD is present if distal pH-metry shows a re-
flux index (% time pH < 4) of > 10% in infants and > 7% (3% to
7% considered indeterminate) in children aged over 12months, as
suggested by theGORDguidelines of the European andAmerican
paediatric gastroenterology groups (Rudolph 2001; Vandenplas
1993; Vandenplas 2009). Dual channel (proximal and distal) oe-
sophageal pH-metry has also been used in assessing GORD with
arguable clinical use even in the assessment of patients at risk for
upper airway complications ofGORD(Rudolph 2001).However,
there is variation in what constitutes an abnormal reflux index;
in adults the definition of abnormal pH-metry consistent with
GORD varies from a reflux index of greater than 3.9% to 7.2%
(AMA 1996).
A systematic review examining the efficacy of the various treatment
modalities for prolonged non-specific cough in adults and children
and GORD would help clarify the link (or otherwise) between
cough and GORD.
O B J E C T I V E S
To evaluate the effectiveness of GORD treatment in adults and
children with GORD and prolonged cough not related to an un-
derlying respiratory disease, i.e. non-specific chronic cough.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials of any GORD treatment with
cough as an outcome, where cough is not primarily related to an
underlying respiratory disorder (such as cystic fibrosis, asthma,
chronic obstructive airway disease, suppurative lungdisease etc.) or
medication use (angiotensin converting enzyme [ACE] inhibitor).
Types of participants
Adults, children or both with chronic (three or more weeks) non-
specific cough (dry and non-productive cough without any other
respiratory symptom, sign or systemic illness).
Exclusion criteria were: cough related to mycoplasma, pertussis
and chlamydia, presence of underlying cardio-respiratory condi-
tion, current or recurrent wheeze (greater than two episodes), pres-
ence of other respiratory symptoms (productive cough, haemopty-
sis, dyspnoea), presence of other respiratory signs (clubbing, chest
wall deformity, respiratory noises such as wheeze on auscultation
and other adventitious sounds), presence of any sign of systemic
illness (failure to thrive, aspiration, neurological or developmental
abnormality) and presence of lung function abnormality.
Types of interventions
All randomised controlled comparisons of therapies for GORD.
We did not include trials only comparing two ormoremedications
without a placebo comparison group. We evaluated the following
treatment regimes:
1. anti-reflux conservative measures;
2. H2 receptor antagonists;
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3. proton pump inhibitors (PPI); and
4. surgical therapy.
We included trials that included the use of other medications or
interventions if all participants had equal access to such medica-
tions or interventions.
Types of outcome measures
We made attempts to obtain data on at least one of the following
outcome measures.
Primary outcomes
Proportions of participantswhowere not cured or not substantially
improved at follow up (failure to cure). Cure is defined as complete
resolution of cough or substantial reduction as predetermined by
trialist, such as 70% reduction in cough indices (Chang 1998b).
Secondary outcomes
1. Proportions of participants who were not cured at follow
up.
2. Proportions of participants who were not substantially
improved at follow up.
3. Mean difference in cough indices (cough diary, cough
frequency, cough scores).
4. Proportions experiencing adverse effects of the intervention
(e.g. rash, surgical morbidity etc.).
5. Proportions experiencing complications (e.g. requirement
for medication change, repeat surgery etc.).
We determined the proportions of participants who failed to im-
prove on treatment and the mean clinical improvement using the
following hierarchy of assessmentmeasures (i.e. where two ormore
assessment measures were reported in the same study, we used the
outcome measure that was listed first in the hierarchy).
1. Objective measurements of cough indices (cough
frequency, cough receptor sensitivity).
2. Symptomatic (quality of life, Likert scale, visual analogue
scale, level of interference of cough, cough diary) - assessed by
the patient (adult or child).
3. Symptomatic (quality of life, Likert scale, visual analogue
scale, level of interference of cough, cough diary) - assessed by
the parents/carers.
4. Symptomatic (Likert scale, visual analogue scale, level of
interference of cough, cough diary) - assessed by clinicians.
5. Relevant airway markers consistent with inflammation.
Search methods for identification of studies
We used the following topic search strategy to identify the relevant
randomised controlled trials listed on the electronic databases:
(“gastro-oesophageal reflux” OR “gastroesophageal reflux” OR
“gastro-esophageal reflux” OR “reflux” OR “ger” OR “gerd” OR
“acid” OR “esophagus” OR “oesophagus”, all as [textword] or
[MeSH]) AND (“cough” as [textword] or [MeSH])
For the full strategies please see Appendix 2; Appendix 3 and
Appendix 4.
We identified trials from the following sources:
1. the Cochrane Controlled Trials Register (CENTRAL),
which includes the Cochrane Airways Group Specialised
Register;
2. MEDLINE 1966 to current (topic search strategy
combined with the MEDLINE randomised controlled trial
search filter as outlined in the Airways Group module);
3. OLDMEDLINE 1951 to 1965 (topic search strategy
combined with the MEDLINE randomised controlled trial
search filter as outlined in the Airways Group module);
4. EMBASE 1997 to current (topic search strategy combined
with the EMBASE randomised controlled trial search filter as
outlined in the Airways Group module);
5. the lists of references in relevant publications; and
6. written communication with the authors of trials included
in the review when necessary.
Searches are current as of April 2010.
Data collection and analysis
Selection of studies
From the title, abstract or descriptions, two review authors (ABC,
LAG) independently reviewed the literature searches to identify
potentially relevant trials for full review. We conducted searches of
bibliographies and texts to identify additional studies. From the
full text using specific criteria, the same two review authors in-
dependently selected trials for inclusion. We measured agreement
using kappa statistics. We resolved disagreement by consensus.
Data extraction and management
We reviewed trials that satisfied the inclusion criteria wand
recorded the following information: study setting, year of study,
source of funding, patient recruitment details (including num-
ber of eligible participants), inclusion and exclusion criteria, cri-
teria used for GOR diagnosis, GOR symptoms, randomisation
and allocation concealment method, numbers of participants ran-
domised, blinding (masking) of participants, care providers and
outcome assessors, dose and type of GORD therapy, duration of
therapy, co-interventions, numbers of patients not followed up,
reasons for withdrawals from study protocol (clinical, side effects,
refusal and other), details on side effects of therapy, and whether
intention-to-treat analyses were possible. We extracted data on the
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outcomes described previously. We requested further information
from the authors if required.
Assessment of risk of bias in included studies
In the previous reviews, we used an assessment score and the Jadad
score. For this update we have removed the Jadad score and in its
place have included a quality assessment based on the Cochrane
Handbook for Systematic Reviews of Interventions (Handbook 2008)
and entered assessments into ’Risk of bias’ (RoB) tables. When au-
thors of papers gave additional data, we based quality assessments
and Jadad scores on additional data supplied. A single review au-
thor our assessed four components in the RoB.
1. Adequate sequence generation.
2. Allocation concealment.
3. Blinding.
4. Free of other bias.
Two review authors (AC and LG) independently performed
the second assessment scoring system and included this in
Characteristics of included studies. We measured inter-review au-
thor reliability for the identification of high-quality studies for
each component using the Kappa statistic. The four components
of quality were assessed:
1. Allocation concealment. Trials were scored as: Grade A:
adequate concealment; Grade B: unclear; Grade C: clearly
inadequate concealment (Grade A = high quality).
2. Blinding. Trials were scored as: Grade A: participant and
care provider and outcome assessor blinded; Grade B: outcome
assessor blinded; Grade C: unclear; Grade D: no blinding of
outcome assessor (Grade A, B = high quality).
3. Reporting of participants by allocated group. Trials were
scored as: Grade A: the progress of all randomised participants in
each group described; Grade B: unclear or no mention of
withdrawals or drop outs; Grade C: the progress of all
randomised participants in each group clearly not described
(Grade A = high quality).
4. Follow up. Trials were scored as: Grade A: outcomes
measured in > 90% (where withdrawals due to complications
and side effects are categorised as treatment failures); Grade B:
outcomes measured in 80% to 90%; Grade C: unclear; Grade D:
outcomes measured in < 80% (Grade A = high quality).
Data synthesis
An initial qualitative comparison of all the individually analysed
studies examined whether pooling of results (meta-analysis) was
reasonable. This took into account differences in study popula-
tions, inclusion/exclusion criteria, interventions, outcome assess-
ment and estimated effect size. We included the results from stud-
ies that met the inclusion criteria and reported any of the out-
comes of interest in the subsequent meta-analyses. In cross-over
trials (Eherer 2003; Kiljander 2000), when data were combined
with those from parallel studies, we only used effect estimates from
the first arm (Elbourne 2002). There is some debate over the han-
dling of cross-over data (Clarke 2003; Elbourne 2002) and we
considered that it was invalid to use second-arm data given the
known period effect of cough (i.e. cough tends to resolve with
time (Chang 2001)) and the likely bias associated with carry-over
effect (studies had short wash out time of two weeks compared to
eight weeks of therapy in each arm).
For the dichotomous outcome variables of each individual study,
we calculated relative and absolute risk reductions using a modi-
fied intention-to-treat analysis. This analysis assumes that partic-
ipants not available for outcome assessment have not improved
(and probably represents a conservative estimate of effect). For pri-
mary outcome, we calculated an estimate of the numbers needed
to treat (NNT) for benefit (NNT-B) and harm (NNT-H) from
pooled data with ’intention-to-treat’ used as the denominator and
calculated using the formula 1/risk difference (Clarke 2003). We
defined event as successful treatment defined by absence of cough
by end of treatment period.
We derived imputed correlation coefficient for calculating stan-
dard deviations of change from baseline (Clarke 2003) from other
studies in the review. We calculated the summary weighted risk ra-
tio and 95% confidence interval (fixed-effect model) using the in-
verse of the variance of each study result for weighting. We pooled
data from similar studies, assuming cough indices were normally
distributed continuous variables. For cross-over studies, mean
treatment differences were calculated from raw data, extracted or
imputed and entered as a fixed-effect standardised mean difference
using generic inverse variance (GIV). This gave a weighted SD
unit difference and 95% confidence intervals (RevMan 2008).We
tested heterogeneity between the study results to see if it reached
statistical significance using a Chi2 test.We included the 95%con-
fidence interval estimated using a random-effects model whenever
there were concerns about statistical heterogeneity.
We did not include gastrointestinal symptoms in the forest plots
as it was not an objective of this review.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis:
We planned an a priori subgroup analysis.
1. Age: adults or children (aged < 18 years and < 12 months).
2. Definition of GORD used: acid GORD defined by pH-
metry or oesophageal biopsy or non-acid/volume (alkaline)
reflux or ’extra-oesophageal reflux’.
3. Intervention type: medical or surgical intervention.
Medical intervention further subgrouped to:
a) H2 antagonist;
b) proton pump inhibitor (PPI); and
c) conservative therapy.
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Sensitivity analysis
We planned sensitivity analyses to assess the impact of the poten-
tially important factors on the overall outcomes:
1. variation in the inclusion criteria;
2. differences in the medications used in the intervention and
comparison groups;
3. differences in outcome measures;
4. analysis using a random-effects model;
5. analysis by treatment received;
6. analysis by intention-to-treat;
7. analysis by study design - parallel and cross-over studies
(added after protocol written).
We planned to test for publication bias using a funnel plot.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
The 2008 search resulted in 432 potential titles. Of these we re-
trieved 10 papers, excluded six papers and included four new stud-
ies. One of the included studies (Wo 2006) was identified from an
excluded paper (Coron 2007) that was a generic review of the sub-
ject. All four studies (Chao 2007; Moukarzel 2007; Pawar 2007;
Wo2006)were supported by the pharmaceutical industry involved
in the product trialled in the study. This updated Cochrane Re-
view now has a total of 19 included studies (18 from the previous
version and one from the current update). See Appendix 1 for de-
tails of the results of previous searches. The 2009 search identified
457 potential titles; 15 papers were retrieved but none fulfilled
inclusion criteria. Two studies were added to the excluded studies
list. The 2010 search identified 460 potential studies, six papers
were retrieved and one RCT (Orenstein 2009) was added.
Included studies
Paediatrics
There were six studies in children; five in infants and one in chil-
dren, with the most recent study (Orenstein 2009) added in the
2010 update. Orenstein and colleagues’ study described increased
cough with thickened feeds as an intervention in a diverse group of
infants with cough and GORD (Orenstein 1992). Although most
in the group were otherwise well infants, some had primary respi-
ratory disease (hence did not have non-specific cough). Four stud-
ies (Chao 2007; Moukarzel 2007; Orenstein 1992; Vanderhoof
2003) reported on the use of specific anti-regurgitation formula
milk (as opposed to thickened formula) in infants with GORD
that included cough as an outcome measure. However, Moukarzel
2007 did not provide data specific to cough in the publication.
Orenstein and colleagues’ study described increased cough with
thickened feeds as an intervention in a diverse group of infants
with cough and GORD (Orenstein 1992). Although most in the
group were otherwise well infants, some had primary respiratory
disease (hence did not have non-specific cough). Three studies
were supported (one in part) by the manufacturers of the milk
utilised (Chao 2007; Moukarzel 2007; Vanderhoof 2003) and we
excluded the other (Xinias 2003) because it was an open non-
randomised (but controlled) trial. Outcome measures of the four
studies on infants varied: in two multi-centre studies (Moukarzel
2007; Vanderhoof 2003), cough was reported as part of a symp-
tom complex (with gag or choke, etc.) and although the authors
provided further information, the data could not be used for anal-
ysis in this review. In one study only a small number of infants
had cough (nine of 81) (Chao 2007) displayed in Analysis 1.1 (no
significant difference between groups).
Therewas a singleRCTonPPI in infants (Orenstein 2009) and the
authors provided additional data specific to cough outcomes that
were not available in the publication. There were no controlled
trials on surgery in infants.
The single study in children (Dordal 1994) included children with
asthma; its exclusion criteria were insufficiently defined to allow
classification of participants as having non-specific cough and it
is unclear if the study was a randomised study. There were no
controlled trials on the use of PPIs or surgery in children.
Adults
In adults, 13 studies were included; eleven were published arti-
cles, one in abstract form (Kopec 2001) and one in a conference
report plus abstract (Ing 1997). We sought additional data from
all but one author(s); six responded but only three (Eherer 2003;
Kiljander 2000; Vaezi 2006) were able to provide additional data
that could be used for the meta-analysis. Although all studies in-
cluded cough that was presumed associated with GOR, criteria
for entry into the studies varied. In six studies, participants en-
rolled through the otolaryngology department and had ’laryngitis’
symptoms (Eherer 2003; Havas 1999; Noordzij 2001; Steward
2004; Wo 2006). One study based in medical clinics also primar-
ily enrolled participants with chronic ’laryngitis’ (Vaezi 2006). In
these studies where subjects were recruited from otolaryngology
clinics, primary lung disease (such as asthma defined by hyper-
responsiveness) as an exclusion criteria were not as stringent as
they were in the studies enrolled through medical outpatients (Ing
1997; Jaspersen 1999; Kiljander 2000; Ours 1999). Mean age of
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participants reported in studies was 46 to 58 years (range 18 to
80 years). Some studies had predominantly males (Eherer 2003;
Ours 1999) whereas others had predominantly females (Kiljander
2000; Steward 2004; Wo 2006). Two studies had similar propor-
tions of males to females (Pawar 2007; Vaezi 2006). In all but one
study (Jaspersen 1999), presence of GOR (or extra-oesophageal
reflux) was confirmed objectively. However in Vaezi 2006 only
29% of participants had pH-metry characteristics of GORD. In
most studies the diagnosis of GORwas made with pH-metry, and
some included dual channels. None of the studies used alkaline or
volume reflux as an entry criteria although oesophageal manome-
try was used in two studies.
There were 10 parallel studies and three cross-over studies, all
of which had wash-out periods of two weeks. Ten studies com-
pared PPI to placebo but varying doses and frequencies were used.
Studies involving participants with ’laryngitis’ (El Serag 2001;
Eherer 2003; Havas 1999; Noordzij 2001; Pawar 2007; Steward
2004; Vaezi 2006) generally used higher doses of PPI (twice-daily
regime). Three studies used omeprazole (Kiljander 2000;Noordzij
2001; Ours 1999), one used esomeprazole (Vaezi 2006) and the
other three studies used a different PPI, pantoprazole (Eherer
2003; Wo 2006), rabeprazole (Pawar 2007; Steward 2004) and
lansoprazole (El Serag 2001; Havas 1999). One study compared
PPI to ranitidine (Jaspersen 1999) and another was a two-facto-
rial design using cisapride and diet intervention (Kopec 2001).
In one study (Steward 2004) all subjects (i.e. both controls and
intervention groups) also received instructions for lifestyle modi-
fication. There was a single study onH2-antagonist versus placebo
(Ing 1997), published only as a report on an oral presentation and
abstract format. Data from this study were presented graphically
(provided by the author) and could not be used as points on the
graph were unclear (number in the study did not equate to the
number of points on the graph). There were no randomised con-
trolled studies assessing surgical interventions.
Length of intervention in the study on H2-antagonist versus
placebo was two weeks each (Ing 1997). In the studies using PPI,
length of intervention was two to three months (or eight to 12
weeks) and two studies had prolonged follow up post-trial (Ours
1999). Outcome measures for all studies were subjective cough
scales of varying types. Two studies had outcome assessments done
midway through trial (Havas 1999; Noordzij 2001), one had sev-
eral evaluations during the trial (Vaezi 2006) but only one of these
studies provided ’during trial’ cough data in the paper (Noordzij
2001). Objective cough monitoring was not used in any study.
In all but one study, gastrointestinal or ’extra-oesophageal’ symp-
toms of GORDwere also outcome measures. Adverse events were
specifically mentioned in six studies.
Risk of bias in included studies
The quality score varied. One study scored as ’high quality’ in
all four categories (Steward 2004). Five studies (Eherer 2003; El
Serag 2001; Ours 1999; Vaezi 2006; Wo 2006) scored as ’high
quality’ in three categories and four studies did have any high-
quality points for all four categories. Agreement between the two
main review authors (AC and LG) for quality of studies was ex-
cellent; weighted kappa score was 0.88 for Jadad score and 0.77
for quality assessment.
In the studies in infants, randomisation and blinding were clearly
described in three studies (Orenstein 1992; Orenstein 2009;
Vanderhoof 2003). Randomisation method and blinding were
not mentioned in the other two studies in infants (Chao 2007;
Moukarzel 2007) or in the study in children (Dordal 1994). In
the adult studies, the randomisation process was clearly described
in four but allocation concealment was unclear in all but one
study (Steward 2004; Figure 1). Method of blinding (i.e. appear-
ance of placebo) was clearly described in five studies (Eherer 2003;
Noordzij 2001; Ours 1999; Vaezi 2006; Wo 2006). There were
only four studies with data (including data that were sought from
authors) that could be utilised as intention-to-treat for selected
analysis (Eherer 2003; Kiljander 2000; Ours 1999; Vaezi 2006)
without making any assumptions.
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Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
An overview of the risk of bias judgements according to the four
domains we applied the tool to is provided in Figure 1. Specific
study and item-level judgements are given in Figure 2.
8Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
The 19 studies included 985 randomised participants (534 paedi-
atrics, 476 adults) with 506 (413 paediatrics, 412 adults) complet-
ing the trials. Seventeen articles were published in English, one in
German (Jaspersen 1999) and another in French (Dordal 1994).
In the updated searches of 2005, 2006 and 2007 three studies (El
Serag 2001; Steward 2004; Vaezi 2006) were found from recent
review articles and the numbers above include these papers. Some
of the trialists responded to requests for data. Although entry cri-
teria were fulfilled in some participants, data on cough alone in
these participants was not available on one study (El Serag 2001)
but was available in the other two studies (Steward 2004; Vaezi
2006).
Paediatrics
There were insufficient data in infants and children that could
be combined for display in the graphs as trials in infants were
too dissimilar. The studies on formula-thickening (Chao 2007;
Moukarzel 2007; Orenstein 1992; Vanderhoof 2003) in infants
found improvement in GORD symptoms referring to the gas-
trointestinal system but data for effect on cough were inconsis-
tent. The smaller study (Orenstein 1992) described a significant
increase in cough frequency post-feeds when thickened feeds were
given (Figure 3; Analysis 3.1). The multicentre study described
decrease in percentage of feeds associated with cough/gag/choke
episodes in infants given pre-thickened milk (Vanderhoof 2003).
Cough/gag/choke was grouped as a secondary outcome and scored
in a binary manner in the study of Vanderhoof and colleagues
(Vanderhoof 2003). We sought additional information which was
provided but the authors were unable to provide data on cough
alone (cough was included in symptom complex with choke or
gag or cough). In the Chao 2007 study, the number of children
with cough was small (n = 9 out of 81 infants who completed
the study) and the difference between groups was not significant
(Analysis 1.1). In the Moukarzel 2007 study, although cough was
an outcomemeasure, cough-specific datawere not presented in the
paper. In the excluded study Xinias and colleagues found no effect
of the anti-regurgitation formula milk on cough (Xinias 2003).
No adverse events were reported in of these studies.
Figure 3. Forest plot of comparison: 2 PPI versus placebo (> 18 years), outcome: 2.1 Clinical failures (still
coughing at end of trial or reporting period).
The sole study on PPI in paediatrics found no significant differ-
ence in cough outcomes between infants in the lansoprazole and
placebo groups. When all children were considered the mean dif-
ference of % days with cough (Analysis 2.1; Figure 4) between
groups was not significant (MD 8.60; 95% CI -2.85 to 20.05).
10Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
There was also no difference between groups (OR 1.61; 95%
CI 0.57 to 4.55) (95% CI = NNT-B of 11 to NNT-H of 8)
when only infants who had a cough at baseline were considered
(Analysis 2.2). For both cough outcomes, the data favoured the
placebo group. Orenstein and colleagues also described “no dif-
ference in efficacy between lansoprazole and placebo for symp-
toms attributed to GERD in infants” (Orenstein 2009). Treat-
ment-emergent serious adverse events (as defined by authors) were
significantly more common in the PPI group (OR 5.56; 95% CI
1.18 to 26.25 (Analysis 2.3), with NNT-H in four weeks of 11
(95% CI 3 to 232), depicted in a Cates plot (Figure 5).
Figure 4. Forest plot of comparison: 3 PPI versus placebo (children), outcome: 3.1 Coughing (% days/week).
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Figure 5. Cates plot: In the control group, 25 out of 1000 had a serious adverse event over 4 weeks,
compared to 123 (95% CI 29 to 399) out of 1000 for the PPI group
Dordal and colleagues describedno significant effect of cisapride or
domperidone on cough presumably secondary to GORD (Dordal
1994).
Adults
Cough outcomes
In the single study comparing PPI toH2-antagonist, 70% of those
on PPI improved versus 30% of participants on H2-antagonist
(Jaspersen 1999). Data from the only study comparing H2-antag-
onist to placebo was presented graphically and showed improve-
ment in cough scores by intervention in all participants and the
effect was significant by two weeks (Ing 1997).
In the 10 studies comparing PPI or cisapride to placebo, all but
two studies showed no difference between improvement of cough
scores in the active versus placebo arms (Eherer 2003; Havas
1999; Kopec 2001; Noordzij 2001; Ours 1999; Steward 2004;
Vaezi 2006; Wo 2006). Only two studies described a significant
difference in favour of PPI (Kiljander 2000; Pawar 2007). In the
meta-analysis the outcomes are described below:
Primary outcome: Failure to cure (outcome 03.01)
This was the only outcome where intention-to-treat data could
be utilised in all included studies (Eherer 2003; Kiljander 2000;
Ours 1999; Vaezi 2006) displayed in the forest plot. The pooled
OR effect estimate was 0.46 and non-significant (95% CI 0.19
to 1.15) (Analysis 3.1; Figure 3), resulting in a NNT of 12 (95%
CI NNT-B of 4 to NNT-H of 90). In Wo and colleagues’ study,
the “% of subjects with adequate relief ” was reported to be similar
in both the PPI group and the placebo group (40% and 42%
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respectively, P = 0.89) (Wo 2006). As data specific for cough could
not be obtained, this study was not included in the meta-analysis.
Mean cough score at end of trial (outcome 03.02)
Ina pooled analysis of four studies (Eherer 2003; Kiljander 2000;
Noordzij 2001; Pawar 2007), the effect of active drug was of bor-
derline statistical significance (SMD -0.38; 95% CI -0.77 to 0,
P = 0.05) (Analysis 3.2). A pooled analysis of data from cross-
over studies (Eherer 2003; Kiljander 2000) was also not significant
(SMD -0.29; 95% CI -0.62 to 0.04).
Change in cough scores at end of intervention (parallel-
group/1st arm cross-over data) (outcome 03.03 to 05)
Pooled analysis for all six studies (Eherer 2003; Havas 1999;
Kiljander 2000; Noordzij 2001; Steward 2004; Pawar 2007) was
statistically significant (SMD -0.39, 95% CI -0.77 to -0.08)
(Analysis 3.3; Figure 6), and there was a moderate level of hetero-
geneity (I2 = 12%). The two studies (Kiljander 2000; Noordzij
2001) which utilised omeprazole showed a significant benefit
(SMD -0.71; 95% CI -1.29 to -0.41) and no significant hetero-
geneity. The studies that utilised other PPIs (lansoprazole, rabepra-
zole or pantoprazole) (Eherer 2003; Havas 1999; Steward 2004;
Pawar 2007) showed no significant benefit of PPI over placebo.
Within each subgroup, there was no significant heterogeneity and
the between-group test for difference between omeprazole and the
other PPIs was non-significant (SMD -0.45; 95% CI -1.13 to
0.23). This subgroup analysis was post hoc. Kiljander 2000 and
Noordzij 2001, the two studies that used omeprazole, were also
the studies that reported data at week four and whilst the study
drugs may have an effect over a longer period than one month, the
evidence from our analyses should be cautiously applied for several
reasons. Firstly the sample sizes of the trials were small and the
sensitivity of the symptom scales is as yet unqualified. However,
data from the two cross-over trials (Eherer 2003; Kiljander 2000)
assessing mean change in symptoms may confer some validity to
the notion that there is an effect on symptom change. When these
data were pooled using change from baseline scores, there was a
significant difference of -0.41 standard deviation units (95% CI -
0.75 to -0.07) (Analysis 3.4). The result with absolute scores was
not statistically significant (Analysis 3.5).
Change in cough scores at week four of intervention
(outcome 03.06)
Two studies (Kiljander 2000; Noordzij 2001) could be utilised
for assessment of time effect i.e. after four weeks of intervention.
The change in cough score was in favour of PPI use but was not
significant (P = 0.09) with a standardised mean difference of -0.51
(95% CI -1.08 to 0.06) (Analysis 3.6).
Change in cough score between week eight (end of
intervention) and week four (mid-intervention) (outcome
03.07)
Two studies (Kiljander 2000; Noordzij 2001) could be utilised
for assessment of time effect from eight weeks (two months) to
four weeks (one month) of intervention. There was no significant
difference between change in cough score between week eight and
week four (SMD of -0.44; 95% CI -1.04 to 0.16) (Analysis 3.7
Determination of time to respond and duration of treatment ef-
fect was limited. The two studies that reported on scores midway
through trial (at one month (Noordzij 2001) and at six weeks
(Havas 1999)) found no difference in scores between midway
scores versus end of trial scores. In the meta-analysis, whereby raw
data was obtained from Kiljander 2000 (data from Havas 1999
could not be included), no significant effect was found between
week eight and week four. In one cross-over study, cough resolved
while on omeprazole in two adults but recurred in the washout
phase (Kiljander 2000). One study that reported time to response
(Ours 1999) was also the only paper that had follow up post-trial
(open non-RCT followed the double-blind, randomised, placebo-
controlled parallel trial). The authors reported that cough totally
resolved or showed a downward decline in cough scores in five
to 14 days in coughers who responded to open-label PPI (Ours
1999).
In contrast to the paediatric data, none of these adult studies re-
ported any significant adverse events to interventions and hence
’number needed to harm’ was not relevant in this review. Hetero-
geneity between studies included for meta-analysis was non-sig-
nificant for all outcomes analysed. The funnel plots for the cough
outcomes were asymmetrical but study numbers were small. As-
sociation between level of risk and benefit was not possible.
Gastrointestinal symptoms of GORD
All studies with sufficient data provided reported significant im-
provement in gastrointestinal symptoms over time but the treat-
ment arm was no different from the placebo arm in five studies
(Eherer 2003; Havas 1999; Noordzij 2001; Pawar 2007;Wo 2006
). In two studies, improvement in GORD symptoms could not
be determined from lack of data or GORD symptoms were pre-
sumed absent (Ing 1997; Kopec 2001).
Laryngeal symptoms and scores
All eight studies that included this outcome measure reported
significant improvement in other laryngitis symptoms over time
(Eherer 2003; El Serag 2001;Havas 1999;Noordzij 2001; Steward
2004; Vaezi 2006; Wo 2006). In six studies, the difference in total
symptom improvement was similar in both the treatment arm and
placebo arms (Eherer 2003; Havas 1999; Pawar 2007; Steward
2004; Vaezi 2006; Wo 2006). One study found significant differ-
ences between PPI and placebo in hoarseness and throat clearing
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but not in throat pain (Noordzij 2001). Another study (El Serag
2001) described that a higher proportion of participants in the
PPI group (86%) had a complete response when compared to the
placebo group (40%) but no significant difference in laryngoscopy
assessment. One study described no difference between PPI and
placebo in total score but an improvement in cough score in favour
of PPI, yet the objective score in reflux (by video laryngoscopy)
significantly favoured the placebo group (Pawar 2007). Wo and
colleagues described that at the four-week follow-up period post-
cessation of treatment, those on PPI had a significantly higher re-
currence of laryngeal symptoms then those on placebo (Wo 2006).
When assessed by laryngoscopy, four studies described significant
improvement in laryngoscopy-based scores but again the improve-
ment in those receiving PPIwas similar to those on placebo (Eherer
2003;Havas 1999; Steward 2004;Vaezi 2006).However,Noordzij
2001 found no significant difference in laryngoscopy scores be-
fore and after treatment in both arms. Pawar 2007 and Wo 2006
described a significant difference between groups, both favouring
the placebo group.
Sensitivity analyses
Limiting the analysis to studies with higher quality scores (Jadad
score of five, as in previous versions) did not change the primary
outcome (proportions not cured) with an OR of 0.52 (95% CI
0.20 to 1.35) (all-inclusive effect estimate was OR 0.46; 95% CI
0.19 to 1.15). It was not possible to perform this on other out-
comes. Varying the inclusion criteria by removing studies of par-
ticipants enrolled from otolaryngology clinics also did not change
the primary outcome (OR 0.17; 95% CI 0.02 to 1.73). Varying
inclusion criteria by limiting studies to participants with ’laryngi-
tis’ also did not change the primary outcome (OR 0.24; 95% CI
0.21 to 1.49). It was again not possible to test this effect on other
outcomes. Varying the inclusion criteria by removing studies of
participants enrolled frommedical clinics did not alter non-signif-
icance of results (altered ’change in cough score’ outcome from all-
inclusive SMD -0.39; 95% CI -0.71 to -0.08 to SMD -0.18; 95%
CI -0.71 to 0.35). ’Mean cough score at end of trial’ did not sig-
nificantly change when medical clinic studies were omitted(SMD
-0.34; 95% CI -0.97 to 0.28) and analysis was not possible for
the primary outcome. It was not possible to test for analysis for
medication class type or study size because of all studies were small
and only studies on PPI could be used in meta-analysis. Analysis
by treatment received did not change the primary outcome, i.e.
proportions not cured (OR 0.3; 95%CI 0.06 to 1.44). As analyses
for other outcomes were performed on ’treatment received’ (in-
tention-to-treat analysis was not possible), this was not repeated
for the other three outcomes. There was no difference in results
when we used a random-effects model in all outcome measures.
When, however, data from both arms of the cross-over studies
were treated as parallel studies, we found a significant difference
between week eight and week four (SMD -0.76; 95% CI -1.27 to
-0.25) suggesting that the non-significant effect is possibly related
to a small sample size.
D I S C U S S I O N
This systematic review of 19 studies (six in infants/children and
13 in adults) has shown a lack of high-level evidence that the treat-
ment of gastroesophageal reflux disease (GORD) associated cough
improves cough measured by subjective methods (i.e. subjective
cough). Studies on milk formula-thickening yielded inconsistent
results and the single randomised controlled trial (RCT) on pro-
ton pump inhibitors (PPI) in paediatrics (162 children) found no
significant difference between groups for cough as primary out-
come (95% CI of number needed to treat for benefit (NNT-B)
of 11 to number needed to treat for harm (NNT-H) of eight) or
other cough outcomes. Importantly, serious adverse events, par-
ticularly lower respiratory tract infections, occurred significantly
more frequently in the lansoprazole group compared with the
placebo group, the NNT-H after four weeks was 11 (95% CI 3 to
232). In adults, there was no significant effect in the pooled analy-
sis and the beneficial effect was seen only in the subgroup analysis.
The OR for cough resolution pooled from four adult studies was
not statistically significant (NNT-B of 4 to NNT-H of 90). This
review also highlights the large placebo and time period effect of
treatment for chronic cough.
The beneficial effects of PPI for cough and GORDwere inconsis-
tent. The only significant differences were change in cough scores
at the end of studies which used omeprazole (Kiljander 2000;
Noordzij 2001; both these studies also reported four weeks change
at which time point there was no significant difference in change in
cough scores) and in the generic inverse variance (GIV) analysis of
cross-over studies (Eherer 2003; Kiljander 2000). Non-significant
changes were found in the primary outcome measure of failure
to cure, as well as in mean cough score at end of trial (borderline
non-significant) and when all studies were combined for change
in cough score at end of trial analysis. While a possible contrib-
utor to this is the lack of power, another possible contributor to
the inconsistent and small treatment effect is that, as cough and
GORD are both common symptoms, the presumed GORD-re-
lated cough was not caused by GORD. This explanation suggests
that in a high proportion of cases of presumed GORD-related
cough, there is in fact an alternative cause for the persistent cough.
Indeed cough is themost common symptom presenting to doctors
(Britt 2002). Both GOR and cough are common diseases, which
often co-exist and this association does not imply cause and effect
(Field 1999). Indeed the probability of both symptoms co-existing
merely by chance is high, and cough can induce reflux episodes
as described in asthma and GORD literature (Field 1999; Zerbib
2002). However, our finding of an effect of therapy with PPI to
improve cough when measured using change scores at the end
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of the trials does suggest that in a proportion of cases of chronic
cough with associated GORD, GORD could be a contributing
cause of cough. However, the non-significant NNT is relatively
large at 12 (95% CI NNT-B of 4 to NNT-H of 90).
Other possible influences on the results of this review include de-
gree of acid inhibition achieved, duration of therapy, outcomes of
cough measured, and type of GORD (acid versus non-acid/vol-
ume reflux). The degree of acid inhibition achieved in the treat-
ment is probably a small factor, if it is a factor at all, given that
in the majority of studies resolution of GORD symptoms (of the
gastrointestinal system) was achieved. However, it is also possi-
ble that different degrees of acid suppression are required to con-
trol the different manifestations of GORD. Subjective cough out-
comes were variable between studies and in all studies the diary
systems used were unvalidated. Subjective cough monitoring is
subject to various influences (Chang 1998) and less reliable than
objective cough monitoring in both adults (Hsu 1994) and chil-
dren (Chang 2003; Chang 1998). In large RCTs, the influence of
the type of outcome measures should be equal in both arms, but
if one medication is more likely to improve symptoms other than
cough, cough-specific symptom reporting may be differentially
influenced. This is relevant as in the majority of included studies
resolution of other GORD symptoms was achieved, which may
have influenced cough-specific reporting.
Some clinical heterogeneity was present in the participants of the
studies included as the majority but not all participants enrolled
from otolaryngology clinics had cough. However, using separate
analysis the direction of change in favour of PPI use was the same
in patients enrolled from medical or from otolaryngology clinics.
Indeed, excluding patients from otolaryngology clinics (or with
laryngitis) did not alter the level of statistical significance of the
primary outcome. There was no significant statistical heterogene-
ity in studies between omeprazole and other PPIs, but these data
are limited by small sample sizes and different doses used by the
different groups of trialists. The studies using omeprazole used ei-
ther 40 mg daily (Kiljander 2000) or twice-daily (Noordzij 2001),
while the dosage for lansoprazole was 30 mg twice-daily (Havas
1999), rabeprazole was 20 mg twice-daily (Steward 2004) and
pantoprazole was 40 mg twice-daily (Eherer 2003). Other out-
come analysis would not be possible without the studies based in
otolaryngology clinics, which would have resulted in non-signif-
icant changes in all the outcomes shown in the forest plots, with
the exception of change in cough scores at the end of intervention
which was significant in the single medical clinic study with data
available. Another recent systematic review on laryngo-pharyngeal
reflux (LPR) (where cough is often a dominant symptom), con-
cluded that “high-dose proton pump inhibitor is nomore effective
than placebo in producing symptomatic improvement or resolu-
tion of laryngo-pharyngeal symptoms” (Gatta 2007).
Resolution of cough in response to effective treatment is the ideal
outcome in these trials. However a clinically significant improve-
ment, rather than total resolution of cough, may be relevant and
acceptable to patients with poor quality of life. The magnitude
of change in cough score that constitutes a clinically relevant im-
provement is unknown. TheNNT for clinical significant improve-
ment (as opposed to cough resolution) is unknown.
Data on length of therapy required to achieve a change in cough
score are inconsistent. One study reported significant improve-
ment after two weeks of H2-antagonist in all participants (Ing
1997), which is a less potent acid-suppressing agent than PPI
(Rudolph 2001). Ours 1999 made specific reference to the re-
sponse time of five to 14 days in those whose cough was relieved
by PPI in the open-label phase. However, in themeta-analysis lim-
ited to two studies where outcomes at four weeks were available
(Kiljander 2000; Noordzij 2001), a trend to improvement was
seen at week four and again at eight weeks but this was not statisti-
cally significant. If data from cross-over trials were analysed as par-
allel trials (i.e. as first-arm data), there was a significant difference
between week eight and week four cough scores. While data on
length of therapy is inconclusive, results from this review suggest
that a trial of at least eight to nine weeks would be long enough to
expect a significant improvement. This is also supported by a RCT
comparing two doses of lansoprazole (30 mg twice-daily to 30 mg
daily). In participants whose cough responded to lansoprazole, the
response was seen by four weeks and extended therapy (12 weeks)
conferred no significant additional benefit (Baldi 2006). There is
no RCT data to support recommendations of a six-month ther-
apy trial, in contrast to uncontrolled observations, that GORD-
associated cough takes a mean of a five to six months to take effect
(Corrao 1996; Irwin 2002a).
PPIs are currently the most potent non-surgical intervention for
acid-GORD and no adverse events were reported in these studies.
The use of these medications as a trial of therapy thus probably
has little risk. However, an epidemiological study reported that
adults on PPI or H2 antagonist have an increased risk of having
community-acquired pneumonia (adjusted relative risk of 1.89
(95%CI1.36 to 2.62) and1.63 (95%CI 1.07 to 2.48) respectively
(Laheij 2004)). This risk translates to “approximately one case
of pneumonia for every 100 years of patient exposure” (Gregor
2004). Another study described an increased risk of hip fractures
associated with PPI use; the adjusted odds ratio for hip fracture
associated with more than one year of PPI therapy was 1.44 (95%
CI 1.30 to 1.59) (Yang 2006). Moreover, use of PPI has been
reported to cause cough (Howaizi 2003) and the package insert
for omeprazole includes cough as an adverse event in 1.1% of
adults. In contrast to pharmaceutical interventions, there were no
randomised studies on surgical intervention, which carries a small
but significant rate of serious adverse events.
Some authors suggest that cough in association with GORD re-
lated to acid reflux can occur with normal pH-metry and indices
(i.e. require reflux index of 0%), and that cough can take a pro-
longed time (a year) to settle post-GORD intervention (Irwin
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2002b). Such assertions are difficult to prove or disprove in the
context of the difficulties with using cough as the primary outcome
measure in studies and the feasibility of the required studies. The
difficulties relating GORD to cough as causative (as opposed to an
association) has been recently summarised (Chang 2010; Eastburn
2007). There is discordance between cough guidelines produced
by adult respiratory groups (which assert thatGORD is a common
cause of cough) to those originating from gastroenterology soci-
eties (which assert that the cause and effect is unclear) (Vakil 2006;
Vandenplas 2009) when attributing cough and GORD. However,
considerations of non-acid reflux require further studies and per-
haps multichannel intraluminal electrical impedance monitoring,
said to be a more sensitive alternative technology for evaluating
all types of GORD (acid and non-acid) (Shay 2004) may prove
useful.
Quality of the evidence
The validity of this systematic review is hindered by the disparate
nature of the interventions considered and the resulting small
number studies, with only selected availability of unpublished
data. Given the distribution of effects for the primary outcome,
this may be a reason to suspect publication bias (Figure 6). Fur-
thermore although 19 studies were identified, data could only be
used for a subset of them. Our efforts to obtain numerical out-
come data from a number of investigators have only been partially
successful. This review is also limited by a lack of validated scales
and objective data on cough as well as a lack of allocation conceal-
ment data and possibly by clinical heterogeneity of participants
and medications. The review is primarily concerned with people
who do not have primary lung disease but this as an exclusion
factor could not be stringently applied in all studies. In all but four
studies (Pawar 2007; Steward 2004; Vaezi 2006; Wo 2006), par-
ticipants were selected for gastro-intestinal symptoms or objective
evidence of GORD and most but not all participants had cough.
GORD criteria also varied between studies which may influence
results. Most studies did not utilise GORD criteria specified by
guidelines published by American and European Gastrointesti-
nal Associations (AMA 1996; Rudolph 2001; Vandenplas 1993).
There are also no data on non-acid reflux.
Figure 6. Funnel plot of comparison: 2 PPI versus placebo (> 18 years), outcome: 2.1 Clinical failures (still
coughing at end of trial or reporting period).
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Potential biases in the review process
The review process was protected from bias by following a pre-
published protocol. We minimised bias by assessing studies in-
dependently and resolving differences of opinion by discussion.
Data extraction was also performed in duplicate to reduce bias. We
also contacted almost all authors for additional data. Many pro-
vided unpublished data (see Acknowledgements section) which
reduced potential bias. However authors from one large negative
study (Vaezi 2006) did not provide additional data and it is likely
that inclusion of data from this study into the meta-analysis (for
’change in cough score’ outcome) would add to the doubt of ben-
efit of PPIs for cough in adults.
Agreements and disagreements with other
studies or reviews
In contrast to the small effect ofGORDtreatment on cough found
in RCTs, in non-controlled trials (see Characteristics of excluded
studies) the improvement rate of surgical intervention forGORD-
associated cough has been reported to be as high as 92% (Wright
2003) with cure rates as high as 81% (Brouwer 2003). For non-
surgical intervention, e.g. with PPI alone (Habermann 2002) or
PPI with motility agents (Poe 2003), cough improvement rates of
86% to 100% have been reported (Habermann 2002; Poe 2003).
The large difference between the effect of treatment of GORD
on cough seen in randomised controlled and uncontrolled trials is
likely related to the period effect and/or placebo effect also reported
in other treatments for cough (Chang 1999). The placebo effect of
cough treatments has been reported to be as high as 85% (Eccles
2002). The high rate of placebo effect was specifically highlighted
in two of the included studies (Eherer 2003; Noordzij 2001).
Another systematic review on laryngo-pharyngeal reflux (LPR)
(where cough is often a dominant symptom), had similar findings
to this review. Gatta et al concluded that “high-dose proton pump
inhibitor is no more effective than placebo in producing symp-
tomatic improvement or resolution of laryngo-pharyngeal symp-
toms” (Gatta 2007).
Also, a small prospective concurrent controlled study (non-ran-
domised) described non-significant difference in the adults with
laryngo-pharyngeal reflux (LPR) (and unresponsive to PPI) who
had laparoscopic Nissen fundoplication versus controls (Swoger
2006).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Cough and gastrointestinal symptoms of GORD are common ail-
ments and the presence of both symptoms by chance is high (in
a cohort of patients with chronic cough, the chance occurrence
maybe as high as 25%) (Eastburn 2007). There is insufficient ev-
idence to conclude that in adults GORD treatment with PPI for
cough associated with GORD is beneficial. The beneficial effect
was only seen in secondary subgroup analysis and is small. Given
the significant morbidity of chronic cough in many patients, a
trial of therapy with PPI in adults with chronic cough and GORD
maybe considered but has to be balanced with the reported in-
creased (but small) risk of pneumonia in adults (Laheij 2004) on
acid suppressant therapy. If a therapeutic or empiric trial of PPI is
undertaken for treatment of cough, symptom improvement seems
most likely to occur by two to eight weeks, although the optimal
duration is uncertain. We would thus recommend that empiric
trials not be abandoned before eight weeks until better evidence is
available.However, the period effect (natural resolutionwith time)
of cough is significant. Clinicians should also be cognisant of the
large influence of placebo intervention seen in studies that utilise
cough as an outcome measure. It is probable that a proportion
of adult patients with chronic cough are subjected to longer-term
PPI because of an initial apparent response due to this placebo
effect, when their cough is in fact not caused by their incidental
GORD. There is insufficient data to support (or refute) common
recommendations of diet manipulation or use of motility agents
either as a single agent or in conjunction with PPIs in the man-
agement of GORD and cough.
In children, based on current data, PPIs should not be used empir-
ically. The single relatively large high quality study on the utility of
PPI for cough associated with GORD found no beneficial effect in
infants and those on lansoprazole had significantly increased seri-
ous adverse events, in particular lower respiratory infections. Data
on milk modification for infants and cough with GORD is insuf-
ficient to make specific recommendations. Until more evidence is
available in the form of well-designed RCTs, other causes of cough
should be considered in children with cough and GORD, prior to
any consideration of empiric treatment with a prolonged course
of GORD medications/interventions.
Implications for research
Despite the widely advocated proposal that GORD-associated
cough is common and that prolonged treatment is required, there
is a paucity of RCT data on how effective GORD management
is in treating cough associated with GORD. Sufficiently pow-
ered RCTs examining time for improvement and resolution of
cough as well as optimal duration of therapy using valid cough
outcomes are required. These cough outcomes should include ob-
jective tools (e.g. ambulatory cough monitors) and validated sub-
jective cough instruments, such as cough specific quality if life
instruments (Birring 2003; French 2002; Newcombe 2008) and
cough diaries (Chang 1998; Hsu 1994). Studies on prediction of
response to treatment would also be useful for clinical practice.
The significant time period effect and placebo influences on cough
as a symptom would render open label studies difficult to inter-
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pret. Design of future RCTs should be parallel and placebo-con-
trolled, and have sufficient follow-up time post-trial to evaluate
the possible carry-over effect or recurrence of cough post-cessation
of therapy. All three cross-over studies reported a significant carry-
over effect (Eherer 2003; Ing 1997; Kiljander 2003); cross-over
designed studies should therefore not be repeated. Objective mea-
surement of reflux (acid and non-acid) whilst on therapy would
also be beneficial. Given the possible significant harm of surgical
intervention and the recommendation of surgical intervention if
cough does not resolve with non-surgical intervention for cough
presumed associated with GORD symptoms (Irwin 1998), the
need for a randomised controlled study of surgical intervention is
substantial. Respiratory illness and pharmacokinetics of medica-
tions (Sinaiko 2001) in children are sufficiently different to that
in adults to warrant separate studies on children using child-ap-
propriate valid outcomes (Chang 2003).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chao 2007
Methods Single centre, double-blinded, randomised, placebo-controlled trial that compared a com-
mercial corn-starched milk anti-reflux (AR) formula to a regular 1.25% strength formula
Infants given regular milk at baseline and scintigraphy performed.Diaries collected and repeat
scintigraphy performed using the intervention formula
Randomisation method not well described. Allocation by envelope
High quality score: B, C, A, B
Study was financially supported by a pharmaceutical industry
Participants 100 included infants, 81 completed the 2-month clinical follow up
Intervention group (n = 41): mean age - 90.2 (SD 26.8) days, 21 males, 20 females
Placebo group (n = 40): mean age - 90.5 (SD 27.4) days, 21 males, 19 females
Only total of 9 children had cough as a symptom
Inclusion criteria: non-breast-fed infants (age 2-4 months) presenting with frequent regurgi-
tation/vomiting (> 3 times/day)
Exclusion criteria: infants with atopic symptoms such as eczema, watery rhinorrhoea or diar-
rhoea suspecting cow’s milk allergy, presence of mechanical obstruction such as infantile hy-
pertrophic pyloric stenosis and malrotation (excluded with an upper gastrointestinal barium
study)
Interventions A cornstarch-thickened anti-reflux formula compared to 1.25% strength regular formula for
2 months
Outcomes Diary: mean frequency of episodes of regurgitation and/or vomiting, mean feeding volume
tolerated as well as associated symptoms (irritability, cough, choking, crying) during the 3
days prior to a visit, and weight gain
90-minute milk scintigraphy with 500 µCI technetium to quantify gastric emptying
Notes -
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not described
Allocation concealment? Unclear Envelope drawing system, no further infor-
mation described
Blinding?
Clinical cure/failure
Unclear Not stated if parents were blinded to type of
formula
Blinding?
Cough frequency or score
Unclear Not applicable for this study
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Chao 2007 (Continued)
Free of other bias? Unclear Insufficient data
Dordal 1994
Methods Controlled parallel study comparing cisapride with domperidone and no treatment (as con-
trol). At baseline, patients were examined clinically. They underwent skin prick tests, spirom-
etry, chest X-ray and gastro-oesophageal imaging (bolus liquid was administered and a com-
puter-generated image traced the path of the liquid through the oesophagus). Gastroe-
sophageal imaging graded from 1 to 4. 1 = normal, 2 = partial retention of bolus (5 to 10
secs), 3 = retention of bolus (10 to 20 secs), 4 = prolonged retention of bolus (> 20 seconds).
If gastroesophageal imaging of child >= 2, child eligible
Drop outs: n = 10, 15.4% of those recruited. 4 drop outs from cisapride group (2 from adverse
events, 2 lost), 2 from domperidone (lost) and 4 from no treatment group (lost)
Randomisation not mentioned, blinding not described and allocation method not described
High quality score: C, C, B, B
Participants 65 children (number screened not given) fromoutpatients with predominant nocturnal cough
(with or without asthma) and GORD symptoms. 15 of the 55 participants who completed
trial had cough without symptoms of asthma
Median age of groups: cisapride - 6.7 years, SD 2.97 (n = 21, 15 males, 6 females); domperi-
done - 7.05 years, SD 3.05 (n = 23, 10 males, 13 females); control - 6.4 years, SD 2.62 (n =
11, 5 males, 6 females)
Inclusion criteria: children with cough (with or without co-exiting asthma), predominantly
nocturnal symptoms, reflux symptoms
Exclusion: none described
Interventions Cisapride (0.2mg/kg 20minutes before eachmeal) with domperidone (0.2mg/kg 15minutes
before each meal) and no treatment (as control) for 12 weeks
All also received the following: withhold food 2 hours before bedtime, reduce intake of acidic
foods, lower size of meals, but increase frequency, raise height of the head of the bed by 10
cm and sleeping on one’s side
Outcomes 1. Symptoms of cough
2. Gastro-imaging
Notes Data on children without asthma were not provided. No significant difference found between
the groups
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomisation method not described
Allocation concealment? Unclear Information not available
Blinding?
Clinical cure/failure
No Controlled trial, no placebo
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Dordal 1994 (Continued)
Blinding?
Cough frequency or score
No Controlled trial, no placebo
Free of other bias? Unclear Unable to assess as too little information
Eherer 2003
Methods Randomised, double-blind, cross-over study comparing pantoprazole versus placebo in adults
with ’laryngitis’ symptoms (includes cough) and GORD (defined on pH-metry). Patients
with inclusion criteria enrolled from outpatients clinic, telescopic video laryngo-stroboscopy
performed and screened for exclusion criteria. Dual channel pH-metry performed and those
with excessive reflux (> 4.5% time pH < 4) were eligible and randomised
Randomisation by blocks of 4 performed by pharmaceutical supplier. Allocation method not
described. Compliance monitoring not described
Drop outs (30% of those randomised) were not described and were not included as treatment
failures in paper, but analysis by intention-to-treat was possible with additional data provided
by authors
High quality score: B, A, A, A
Participants 21 adults (mean age 48 years, range 20 to 70, 16 males, 5 females) randomised from eligible
22 patients; (62 patients screened) with GORD (diagnosed on pH-metry) and symptoms of
laryngitis (cough, nocturnal cough, sore throat, hoarseness, sore dysphonic attacks, globus
sensation) attending otolaryngeal clinic in a tertiary institution (Karl-Franzens University,
Austria). 12 of the 21 had chronic cough, 7 were initially commenced on placebo, and 5 on
pantoprazole. 4 of those with cough (25%) did not complete trial; 2 in each arm
Inclusion: hoarseness for > 2 months, laryngitis or other laryngeal symptoms which includes
cough
Exclusion: smokers, other causes of laryngitis, prior operations on laryngeal area, laryngeal
malignancy, COPD
Interventions Placebo or pantoprazole 40 mg bd for 3 months, 2 weeks wash out followed by pantoprazole
or placebo for 3 months
Outcomes 1. Laryngeal symptoms (0 to 72) = sumof frequency of each symptomby intensity of symptom
2. Oesophageal symptoms (0 to 48) = sum of frequency of each symptom by intensity of
symptom
3. Laryngeal scoring
All scored at 2 weeks after completion of treatment phase
Notes Raw cough scores were scores provided by Dr Eherer
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation by blocks of 4 performed by
pharmaceutical supplier
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Eherer 2003 (Continued)
Allocation concealment? Unclear Information not available
Blinding?
Clinical cure/failure
Yes Placebo-controlled study, identical appear-
ance
Blinding?
Cough frequency or score
Yes Placebo-controlled study, identical appear-
ance
Free of other bias? Yes Possible but unlikely given that raw data
were supplied, negative study despite support
from pharmaceutical company. Good follow-
up rate (> 90%)
El Serag 2001
Methods Randomised, double-blind , parallel study comparing lansoprazole versus placebo in adults
with ’laryngitis’ symptoms (includes cough) with or without GORD (defined on pH-me-
try). Patients with inclusion criteria enrolled from otolaryngology outpatients clinic. Video
laryngoscopy, dual channel pH-metry, gastroscopy (some also had oesophageal manometry)
performed
Allocation method not described. Compliance monitoring by pill counting
Drop outs (n = 2, 9% of those randomised), one from each arm
High quality score: B, A, B, A
Participants 22 adults randomised from 27 patients screened, with laryngitis with or without GORD
(diagnosed onpH-metry) and symptomsof laryngitis attending otolaryngeal clinic in a tertiary
institution (Houston, Michigan). 14 (64%) of participants had chronic cough. Distal reflux
defined as DeMeester score > 14.7. 21 males, 1 female in study, mean age 59 (SD 12) years
in lansoprazole group, 65 (SD 12) years in placebo group
Inclusion: has (a) ’laryngitis’ symptoms as described in outcome measures, (b) posterior laryn-
gitis as assessed by video laryngoscopy and (c) absence of concurrent infections or allergic
causes of laryngitis
Exclusion: aerodigestive malignancies, radiation therapy, or previous GI surgery
Interventions Lansoprazole 30 mg bd or placebo bd for 3 months
Outcomes 1. Symptoms of hoarseness, frequent clearing of throat, dry cough, globus or persistent sore
throat for > 3 weeks
2. Laryngoscopy findings (no scale used for either)
Notes Authors contacted for further information but no data were provided
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated in blocks of 4
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El Serag 2001 (Continued)
Allocation concealment? Unclear Allocation method not described
Blinding?
Clinical cure/failure
Yes Placebo-controlled study, identical appear-
ance
Blinding?
Cough frequency or score
Yes Placebo-controlled study, identical appear-
ance
Free of other bias? No Unequal baseline characteristics for cough. 9
of 12 in PPI group, 5 of 10 in placebo group.
Supported by pharmaceutical company
Havas 1999
Methods Randomised, double-blind, parallel study comparing lansoprazole versus placebo in adults
with ’posterior pharyngolaryngitis’ symptoms (includes cough) with or without GORD (de-
fined on pH-metry). Patients with inclusion criteria enrolled from otolaryngology outpatients
clinic. Video laryngoscopy, dual channel pH-metry, gastroscopy and oesophageal manometry
performed
Randomisation and allocation method not described. Compliance monitoring not described
Drop outs (n = 5, 25% of those randomised) data on which group was not given and not
included in paper’s analysis or described as treatment failures
Quality score: B, A, C, D
Participants 20 adults randomised from 100 patients screened, with laryngopharyngeal reflux with or
without GORD (diagnosed on pH-metry) and symptoms of laryngitis attending otolaryngeal
clinic in a tertiary institution (Prince of Wales Hospital, Sydney). Distal reflux defined as pH
< 4 for > 4% of time, proximal = pH fall of >= 3 within nadir of =< 5 with oesophageal
acidification. Of the 15 (7 males, 8 females, mean age 52.9 years) who completed the trial, 8
received lansoprazole and 7 placebo
Inclusion: has ’posterior pharyngolaryngitis’ assessed by video laryngoscopy and symptoms
(described in outcome measures)
Exclusion: severe neurological disorders, chronic airflow limitation, pre-existing anti-secretory
medications, severe oesophagitis seen at endoscopy, professional voice users (singers)
Interventions Lansoprazole 30 mg bd or placebo bd for 12 weeks
Outcomes 1. Symptom scores (addition of scores for severity (0 to 3) to scores for frequency (0 to 4))
for each of 4 symptoms of laryngitis (chronic cough, hoarseness, throat clearing, sore throat
pain)
2. Reflux symptoms scored as above for dysphagia, retrosternal burningpain, acid regurgitation
and odynophagia
3. Laryngoscopy findings (0 to 4)
4. Adverse events
Scores obtained at 6 and 12 weeks and data on cough alone were provided in paper
Notes Authors contacted for further information but no data were provided
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Havas 1999 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomisation method not described
Allocation concealment? Unclear Information not available
Blinding?
Clinical cure/failure
Yes Placebo-controlled study, identical appear-
ance
Blinding?
Cough frequency or score
Yes Placebo-controlled study, identical appear-
ance
Free of other bias? Yes Outcomes in 80% to 90%
Ing 1997
Methods Double-blind, cross-over study comparing ranitidine with placebo. Patients with chronic
persistent cough (> 2 months) with unknown aetiology after a standard diagnostic evaluation
were evaluated. They underwent pH-metry and histamine airway hyper responsiveness. pH-
metry was repeated in 7 participants, 4 to 6 weeks after the ranitidine treatment period
Drop outs (n = 1, 4% of those recruited)
Quality score: B, A, C, C
Participants 25 patients randomised (number screened not given) from medical outpatients of a tertiary
hospital. All patients had PD20 to histamine > 8 umols. 13 participants had placebo medica-
tion in the first treatment period, and the 11 patients who had ranitidine in the first treatment
period (1 drop out described)
Mean age was 46.8 (SEM 3.3) years, 11 male, 14 female
Inclusion: chronic cough and significant gastro-oesophageal reflux (presence of > 12 reflux
episodes per 24 hours and time pH < 4 was > 0.7%)
Exclusion: patients with bronchial asthma, chronic bronchitis, allergic rhinitis, sinusitis, post-
nasal drip, other respiratory and cardiac diseases, acute respiratory infections occurring within
2 months of the study, smokers or using theophylline or angiotensin converting enzyme
inhibitors
Interventions Placebo or ranitidine 150 mg bd for 2 weeks, 2 weeks wash out followed by ranitidine or
placebo for 2 weeks
Outcomes 1. Cough scores (1 to 4) on a twice-daily on diary cards
2. Presence of symptoms of GORD
Notes Study not published other than in abstract and conference report. Additional data obtained
from Dr Ing
Risk of bias
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Ing 1997 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomisation method not described
Allocation concealment? Unclear Information not available
Blinding?
Clinical cure/failure
Yes Placebo-controlled study, identical appear-
ance
Blinding?
Cough frequency or score
Yes Placebo-controlled study, identical appear-
ance
Free of other bias? No Study only published in abstract and review
paper format
Jaspersen 1999
Methods Randomised, parallel study comparison of omeprazole versus ranitidine. Method of allocation
not described. Study was not double-blinded
Compliance monitoring not mentioned
No withdrawals reported
Quality score: B, C, B, C
Participants 20 adults from outpatients department, with chronic cough, with otherwise normal lung
function and negative clinical and radiological findings. 10 participants in omeprazole group
(5 males, 5 females, mean age 49.4 years SD 16.3) and 10 in ranitidine group (6 males, 5
females, mean age 46.5 SD 19.7)
Inclusion: persistent cough for 8 weeks, negative findings from physical examination, negative
radiological findings, with either symptoms of GORD or positive investigation of GORD
(diagnosed by gastroscopy), and normal lung function
Exclusion: diagnosis of chronic asthma, COPD, chronic bronchitis, other oesophageal disease,
ACE inhibitor therapy, ENT abnormalities, or smokers
Interventions Omeprazole 10 mg/day or ranitidine 300 mg/day for 8 weeks
Outcomes 1. Cough score (range 0 to 4)
2. Oesophagitis score (range 0 to 4)
3. Adverse events
Outcomes recorded for 8 weeks
Notes -
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Information not available
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Jaspersen 1999 (Continued)
Allocation concealment? Unclear Information not available
Blinding?
Clinical cure/failure
No No placebo
Blinding?
Cough frequency or score
No No placebo
Free of other bias? Unclear Insufficient data available
Kiljander 2000
Methods Randomised, double-blind, cross-over study comparing omeprazole versus placebo in adults
with chronic cough andGORD (defined on pH-metry). Patients with chronic cough enrolled
from pulmonary outpatients clinic were screened for exclusion criteria. Patients completed 1-
week observation by diary cards, pH-metry then performed and those with excessive reflux
were randomised
Randomisation and allocation method not described
Compliance monitored by pill counts after treatment period
8 did not complete trial (27% of those randomised) were not further described and were not
included as treatment failures. Analysis by intention-to-treat for primary outcome only
High quality score: B, A, A, D
Participants 29 adults (median age 49, IQR 20-74, 10 males, 19 females) randomised from 48 patients
screened, with GORD (diagnosed on pH-metry) and chronic (>= 2 months) cough attending
pulmonary clinic in a tertiary institution (Turku University, Finland). 12 initially randomised
to placebo and 9 to omeprazole
Inclusion: chronic persistent cough (>= 2 months)
Exclusion: abnormal chest or sinus radiology, positivemethacholine test, rhinitis, nasalmucosa
appearance of cobblestone or muco-purulent secretions, smokers, asthma, chronic bronchitis,
use of angiotensin converting enzyme inhibitor
Interventions Omeprazole 40 mg per day or placebo for 8 weeks, 2 weeks washout followed by omeprazole
or placebo
Outcomes 1.Weekly daytime cough and night-time cough (cough disturbing sleep) scores = sum of daily
4-point (0 to 3) scale of symptoms (both have range of 0 to 21)
2. Weekly gastric symptoms (heartburn, regurgitation, chest pain) = sum of daily 4 point (0
to 3) scale of symptoms (range 0 to 63). Average of last 3 weeks at end of each treatment
period (8 weeks)
Notes Cough scores obtained from primary author
Risk of bias
Item Authors’ judgement Description
31Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kiljander 2000 (Continued)
Adequate sequence generation? Unclear Randomisation by pharmaceutical company
that sponsored trial but no details
Allocation concealment? Unclear Information not available
Blinding?
Clinical cure/failure
Yes Placebo-controlled study, identical appear-
ance
Blinding?
Cough frequency or score
Yes Placebo-controlled study, identical appear-
ance
Free of other bias? No All outcomes not mentioned, drop out rate
high (27%). Sponsored by pharmaceutical
company
Kopec 2001
Methods Partial double-blind, parallel, randomised, placebo-controlled trial comparing diet and/or
cisapride (2-factorial design). Randomisation of the diet was not blinded, randomisation of
cisapride was double-blinded
After standard diagnostic work-up for chronic cough, participants who met criteria (authors
assume that this predicts patients have an approximate 92% chance of having chronic cough
due to GORD) were randomised and pH-metry performed
Randomisation and allocation method not described
Drop outs (n = 2, 9.5% of those randomised) were not described and were not included as
treatment failures. Analysis by intention-to-treat not possible
Compliance monitoring not described
Quality score: B, C, C, C
Participants 21 adults (mean age 53.5 years, SD 12.9) with chronic cough and GORD randomised from
outpatients clinic (number of eligible patients not given). GORD diagnosed on pH-metry or
on barium meal
Inclusion: adults with chronic cough (> 8 weeks) and presumably GORD-related cough
Exclusion: age < 18 years, pregnancy, known contraindications to receiving cisapride, such
as known allergy to the medication, or prolonged QT interval on EKG or concurrent use of
medications that might interact with cisapride to place the patients at risk of a potentially
life-threatening cardiovascular complication
Interventions 2 factorial design using usual care diet or anti-reflux diet and cisapride 10 mg qid or placebo
for 4 months trial, i.e. 4-arm study
Outcomes Cough scores measured by visual analogue score (VAS) from 0 to 100
Notes No difference found in VAS between groups
Further data provided by author was insufficient for inclusion into meta-analysis
Risk of bias
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Kopec 2001 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Information not available
Allocation concealment? Unclear Information not available
Blinding?
Clinical cure/failure
Unclear Abstract title indicated double-blind study
but insufficient information on placebo
Blinding?
Cough frequency or score
Unclear Abstract title indicated double-blind study
but insufficient information on placebo
Free of other bias? Unclear Insufficient data available
Moukarzel 2007
Methods Single centre, double-blinded, randomised, placebo-controlled trial that compared a com-
mercial pre-thickened anti-reflux (AR) formula to a regular formula
Medical history was obtained and complete physical examination was performed at entry. All
infants underwent a 24-hour oesophageal pH monitoring while receiving alternating normal
and anti-reflux milk. Weekly monitoring of episodes of regurgitation, vomiting, coughing,
crying and stool frequency and consistency. The volume of each feeding during a 24-hour
period once-weekly was also recorded
Randomisation and allocation method not well described
Quality score: B, C, A, B
Study was financially supported by a pharmaceutical industry
Participants 74 included infants, 60 completed the 1-month clinical follow up. Mean age of group was 3.
24 (SD 1.28) months, 40 males, 34 females. Intervention group n = 28, Placebo group n =
32. Mean age of infants within each group was not described
Inclusion criteria: non-breast-fed infants (aged < 6 months) with GOR (determined using
Orenstein criteria)
Exclusion criteria: breast-fed and premature infants, infants with history of wheezing, aspi-
ration pneumonia, apnoea, failure to thrive, anaemia, bleeding, laryngitis and apparent life-
threatening events. Infants already receiving AR or medications that could affect the motility
of the gastrointestinal tract. Parents who subjected infants to overfeeding, dilution errors and
inadequate feeding technique
Interventions A pre-thickened anti-reflux formula compared to regular formula for 1 month
Outcomes Diary: episodes of regurgitation, vomiting, coughing, crying and stool frequency and consis-
tency
Data relating to pHmonitoring (reflux index, oesophageal clearance, etc), electrogastrography
(a cutaneous recording of gastric myoelectrical activity
Notes Wrote to authors 31 May 2008
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Method not described
Allocation concealment? Unclear Information not available
Blinding?
Clinical cure/failure
Unclear Uncertain if parents or investigators knew
which formula infants were on
Blinding?
Cough frequency or score
Unclear Uncertain if parents or investigators knew
which formula infants were on
Free of other bias? Unclear Supported by pharmaceutical company
Noordzij 2001
Methods Randomised, double-blind, parallel study comparing omeprazole versus placebo in adults
with ’laryngitis’ symptoms (includes cough) and GORD (defined on pH-metry)
Patients with inclusion criteria enrolled from outpatients clinic. Video-laryngo-stroboscopy
performed and screened for exclusion criteria. Dual channel pH-metry then performed and
those with reflux were eligible and randomised
Randomisation and allocation method not described
Compliance monitoring not described
Dropouts (6.7%of those randomised)were included in analysis but not described as treatment
failures. Analysis by intention-to-treat not possible
Quality score: B, A, A, B
Participants 30 adults randomised from 53 patients screened) with GORD/laryngopharyngeal reflux (di-
agnosed on pH-metry) and symptoms of laryngitis attending otolaryngeal clinic in a tertiary
institution (University of Virginia). 15 participants in omeprazole group (8 males, 7 females,
mean age 51.7 years) and 15 in placebo group (8 males, 7 females, mean age 45.3). 2 (6.7 %)
did not complete trial, one from placebo group and the other unknown
Inclusion: one or more symptoms of laryngitis for > 3 months, i.e. symptoms of chronic
cough, hoarseness, excessive phlegm, throat clearing, throat pain, lump in throat and acid
reflux (> 4 episodes proximal pH < 4 or 3-point drop in pH with simultaneous drop in distal
pH of < 4)
Exclusion: viral or bacterial laryngitis (undefined), benign vocal fold lesions, occupational
exposures causing laryngitis, history of seasonal allergies or laryngeal malignancy
Interventions Omeprazole 40 mg bd or placebo bd for 2 months
Outcomes 1. Symptom scores (multiplication of severity (0 to 100) of symptom by frequency (number
of days over last 2 weeks) for each of 6 symptoms of laryngitis (chronic cough, hoarseness,
excessive phlegm, throat clearing, throat pain, lump in throat) and 3 symptoms of GOR
(dysphagia, odynophagia and heartburn)
2. Adverse events
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Scores obtained at 1 and 2 months and data on cough alone were provided in paper
Notes Authors contacted for further information but no data were provided
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Method not described
Allocation concealment? Unclear Information not available
Blinding?
Clinical cure/failure
Yes Placebo-controlled study, identical appear-
ance
Blinding?
Cough frequency or score
Yes Placebo-controlled study, identical appear-
ance
Free of other bias? No Supported by pharmaceutical company
Orenstein 1992
Methods Randomised, single-blind, cross-over study comparing thickened and unthickened feeds on
cough associated with feeds, related to GORD diagnosed by pH-metry, barium swallow or
oesophageal biopsy. Assessor was blinded but not care-giver/nurse who fed infants
Randomisation well described (lottery) but allocation method not described
No drop outs mentioned. Uncertain if analysis was by intention-to-treat
Quality score: B, B, B, C
Participants 25 infants randomised (number screened not given) from outpatients of a tertiary gastroen-
terology centre (Children’s Hospital of Pittsburg) referred for GORD
Median post-natal age 7.5 weeks (range 2 to 26), corrected age 7 weeks (6 to 26), gender not
given. Symptoms other than cough were irritability in 72%, regurgitation in 60%, apnoea in
28%, history of pneumonia in 4%
Inclusion criteria: not defined
Exclusion: concurrent acute infectious respiratory illness, use of prokinetic or acid reducing
medications
Interventions Thickened (with rice cereal) and unthickened feeds
Outcomes Cough frequency during feeds and post-prandial per hour
Notes Results showed that cough frequency when on thickened feeds (3.9) was significantly higher
than when on unthickened feeds (2.2); P = 0.006
Risk of bias
Item Authors’ judgement Description
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Orenstein 1992 (Continued)
Adequate sequence generation? Yes Randomisation by lottery in blocks of 10
Allocation concealment? Unclear Information not available
Blinding?
Clinical cure/failure
Unclear Blinding not described
Blinding?
Cough frequency or score
Unclear Blinding not described
Free of other bias? Unclear Non-pharmaceutical company study. Insuffi-
cient data available
Orenstein 2009
Methods Multicentre, randomised, double-blind, placebo-controlled, parallel-group study in infants
with symptomatic GORD who remained symptomatic with crying, fussing, or irritability
(designated ’crying’ hereinafter) during or within 1 hour after feeding despite at least 1 week
of non-pharmacologic management (NPM). NPM consisted of: (1) reduction of tobacco
smoke exposure, (2) 1 or more feeding strategy (frequent burping, frequent small feedings,
use of hypoallergenic and thickened formula, or dairy avoidance by breast-feeding mother)
, and (3) 1 or more positioning strategy (minimising seated and awake supine positioning,
avoiding vigorous handling, particularly post-feeding). Symptomatic GORDdefined by score
on validated Orenstein GORD questionnaire (I-GERD-MH)
Study comprised of 3 periods: pretreatment (1 to 2 weeks before randomisation), treat-
ment (maximum 4 weeks of study drug treatment), and post-treatment. Infants were further
screened through parental completion of the Infant Gastroesophageal Reflux Questionnaire
Medical History (I-GERQ-MH) and by 7 to 14 days of NPM before randomisation
In pretreatment phase, parents were required to institute and record in a daily diary NPM
strategies and outcomes. Randomisation qualification was then assessed - eligible if NPM
failed to reduce meal-related crying to < 25% of all feedings during the final 4 pretreatment
period days
Treatment phase: after 1 week of double-blind treatment, infants discontinuing the treatment
due to inefficacy (as judged by the site investigator) were eligible for open-label lansoprazole
at the investigator’s discretion and with parent consent
Post-treatment phase: telephone calls and a safety follow-up visit with global symptom assess-
ment (GA) of symptoms 30 days after the last dose of any study drug (double-blind or open-
label). The subjects also completed daily diaries for 7 days before the safety follow-up visit
Treatment assigned through a central web-based system according to a schedule that was
computer-generated
Compliance was assessed at study visits based on the number of returned kits, daily diaries
and parental interview. Compliance (>= 90% drug given) achieved in 93% of subjects in
lansoprazole group and 95% in placebo group
Quality score: A, A, A, C
Participants 162 infants randomised (81 in each group)
Lansoprazole group: median (range) age = 16 weeks (4 to 49), 47% male
Placebo group: median (range) age = 18 weeks (4 to 51), 53% male
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No significant difference in any baseline characteristic between groups. At baseline, coughing
present in 75% infants in lansoprazole group and 72% in placebo group. Percentage days
coughing per week was 55% in both groups
96 (49 in lansoprazole group and 47 in placebo group) completed double-blind study. Further
53 completed open-label study
Inclusion criteria: infants age 28 days to 12 months (for preterm infants, corrected age of 44
weeks but 12months)with symptomaticGORD.Weight >2.0 kg anddaily diary documented
crying during or within 1 hour after 25% of feeds during the 4 days before randomisation
despite 7 days of specified NPM strategies
Exclusion criteria were: (1) several categories of unstable clinically significant disease, labora-
tory results or surgery; (2) coexisting oesophageal disease or upper gastrointestinal congenital
anomaly; (3) participation in other drug research; (4) previous use of a PPI within 30 days or
a H2RA within 7 days; (5) discontinuation of previous H2RA for study eligibility; (6) allergy
to any component or excipient of any PPI; (7) requirement for continuous tube feedings; (8)
history of acute life-threatening events attributed to GORD; (9) unstable doses or levels of
various medications; and (10) anticipated non-compliance
Interventions Lansoprazole (or equivalent identical placebo) was administered once daily, preceded and
followed by a 30-minute fast, at 0.2 to 0.3 mg/kg/day for infants age 10 or less weeks and at
1.0 to 1.5 mg/kg/day for those age > 10 weeks. Dosing, based on age and weight on day 1 of
the double-blind treatment, was unchanged during the treatment
Outcomes Parent recorded daily diaries of feeding dates/times and symptoms (crying, regurgitation,
stop feeding, refuse feed, arching back, wheezing, coughing, hoarseness), global assessment
by parents and investigators. Adverse events (including respiratory infections) and laboratory
data. Treatment-emergent adverse events (AEs) encompassed all AEs with onset or worsening
on or after day 1 of drug exposure up to 30 days after last dose; treatment-related AEs
were treatment emergent AEs considered by site investigators to have a definite or possible
relationship to the study drug
Daily dairy recorded for >= 90% days available in 96% of subjects in lansoprazole group,
100% in placebo group
Primary efficacy variables were daily diary-documented number and duration of crying
episodes during or =< 1 hour after feeding
Notes Wrote to authors 23 April 2010
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Double-blind treatment assignments were
made through a central web-based system ac-
cording to a schedule that was computer-gen-
erated by Takeda Global Research & Devel-
opmentCenter, Inc and concealed from study
personnel
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Orenstein 2009 (Continued)
Allocation concealment? Yes Double-blind treatment assignments were
made through a central web-based system ac-
cording to a schedule that was computer-gen-
erated by Takeda Global Research & Devel-
opmentCenter, Inc and concealed from study
personnel
Blinding?
Clinical cure/failure
Yes Placebo-controlled study, identical appear-
ance
Blinding?
Cough frequency or score
Unclear Not applicable here
Free of other bias? Yes Multicentre study. Although supported by
pharmaceutical industry, negative study pub-
lished
Ours 1999
Methods Randomised, double-blind, parallel comparison of omeprazole versus placebo in adults with
chronic cough and GORD (defined on pH-metry). Potential participants screened for exclu-
sion criteria. Patients completed 2 weeks observation by diary cards. Those with score of at
least 3 were treated with antihistamine and nasal corticosteroids. If persistent cough remained
(score >= 2) oesophageal manometry and pH-metry were undertaken. Those with GORD
were randomised. No withdrawals. After end of trial (12 weeks), open study performed using
omeprazole (1 month)
Randomisation by computer but allocation method not described. Compliance monitored
by pill counts after treatment period
All completed trial. Analysis by intention-to-treat possible
Quality score: B, A, A, A
Participants 17 participants randomised from 71 patients screened. Patients with chronic cough enrolled
fromnewspaper advertisements and outpatients (most were enrolled from community). Mean
age and duration of cough in those randomised were not given. Median age of 36 patients in
study prior to results of pH-metry was 58 years with cough duration of 5 years (interquartile
range 2 to 10)
Inclusion: aged 18 to 80 years with chronic cough (>= 6 weeks) with score of >= 2 and with
excessive acid reflux distally or proximal (defined by pH-metry)
Exclusion: abnormal chest radiology, positive methacholine test, smokers, ex-smokers =< 3
months or >= 20 pack-year history of smoking, upper respiratory infection within 8 weeks of
entry, use of angiotensin converting enzyme inhibitor or beta blockers, unable to be weaned
off some medications (corticosteroids, methylxanthines, cough suppressants, beta agonist,
anti-cholinergics, or anti- inflammatory agents), history of pulmonary disease, malignancy or
any co-morbid condition requiring treatment
Interventions Omeprazole 40 mg bd or identical appearing placebo for 12 weeks
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Ours 1999 (Continued)
Outcomes Cough severity and cough frequency scale (0 to 8), day and night, measured daily by diary
cards for 12 weeks
Response to treatment defined as weekly cough frequency combined with severity score for
daytime or night-time cough of =< 1 for >= 2 weeks consecutively
Notes Paper provided failure and success rates but no details on cough scores that can be entered for
other meta-analysis
Open trial results not used for analysis
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated program used
Allocation concealment? Unclear Information not available
Blinding?
Clinical cure/failure
Yes Placebo-controlled study, identical appear-
ance
Blinding?
Cough frequency or score
Yes Placebo-controlled study, identical appear-
ance
Free of other bias? Yes Good follow up and outcomes described
Pawar 2007
Methods Single centre, double-blinded, randomised, placebo-controlled trial that compared twice-daily
rabeprazole with placebo for 90 days in adults with “post nasal drip (PND), throat clearing
or excessive throat mucus”
Subjectswere recruited fromotolaryngology clinic atMedical College ofWisconsin or through
newspaper advertisements. Rigid nasal endoscopy, 2-site 24-hour pharyngeal pH probe mon-
itoring (pH threshold = 5) and video laryngoscopy performed before Rx. Video laryngoscopy
and other 2 outcomes below repeated on day 90
Non-prescription antacids (including H2 antagonists and other PPIs), anti-histamines, de-
congestants disallowed to be used concomitantly
Randomisation method and allocation method not described
Quality score: B, A, B, B (no intention-to-treat analysis)
Study was financially supported in part by a pharmaceutical company
Participants 180 people screened. Of these 53 subjects enrolled, 47 (89%) completed study
Rabeprazole group: n = 21 (11 males, 10 female), mean age = 55.6 years (range 40 to 75)
Placebo group: n = 26 (12 males, 14 female), mean age = 54.3 years (range 24 to 76)
Inclusion: aged 18 to 80 with main complain of PND, throat clearing or excessive throat
mucous
Exclusion: acute or chronic sinus disease (using nasal endoscopy and/or coronal sinus CT
scan), acute rhinosinusitis, nasal polyps or neoplasms, subjects with vasomotor rhinitis or
GOR treated in preceding 2 months, smoking, oesophageal or gastric surgery, cardiovascular
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diease, allergies or pregnancy
Interventions Rabeprazole (20 mg, orally twice-daily) or placebo for 90 days
Outcomes Visual analogue scales for PND symptoms, reflux symptom index (higher score = worse), and
reflux finding score (RFS) (higher score = worse)
Notes Symptomatic score significantly improved in intervention arm but the objective score (RFS)
was significantly worse. Wrote to authors 30 May 2008
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not described
Allocation concealment? Unclear Randomised by research pharmacist but in-
sufficient data provided
Blinding?
Clinical cure/failure
Yes Placebo-controlled study, identical appear-
ance
Blinding?
Cough frequency or score
Yes Placebo-controlled study, identical appear-
ance
Free of other bias? Unclear Study supported by pharmaceutical company
Steward 2004
Methods Single-centre, randomised, double-blind, parallel comparison of rabeprazole versus placebo
in adults with chronic cough and GORD (defined on pH-metry). Potential participants
screened for exclusion criteria. Patients completed underwent video strobo-laryngoscopy and
undertook questionnaire. 24-hour dual probe pH-metry was initially part of protocol but was
later optional (as patients poorly tolerated it)
Randomisation by computer-generated randomnumber table and allocation concealed (using
sealed envelopes). Compliance to PPI/placebo not described
Analysis available for 30 of the 42 (71.4%) subjects randomised. Intention-to-treat data not
available
High quality score: A, A, B, C
Participants 194 patients screened, 42 randomised. Patients enrolled from an academic otolaryngology
practice at the University of Cincinnati, USA and from poster and newspaper advertisements.
Rabeprazole group (n = 21): mean age (SD) = 52.8 (11.5), 23% males. Placebo group (n =
21): mean age (SD) = 45.8 (11.2), 33.3% males
Inclusion criteria: 1) age > 18 years; 2) history of hoarseness, throat clearing, non-productive
cough, globus sensation, or sore throat > 4 weeks; and 3) physical examination consistent
with diagnosis of laryngo-pharyngeal reflux (i.e. oedema, erythema, and/or pachydermia)
Exclusion criteria included: 1) previous surgery for gastroesophageal reflux disease, or current
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gastrostomy tube; 2) history of hypersecretory disorder (i.e. Zollinger Ellison); 3) current
tracheotomy tube; 4) current or recent (within 1 month) use of a proton pump inhibitor;
5) current or recent (within 1 month) use of a histamine-2 receptor blocker (except over the
counter use on an as-needed basis < 3 times per week); 6) allergy to proton pump inhibitors;
7) current systemic steroid therapy; 8) previous laryngeal or hypopharyngeal neoplasm; 9)
previous radiation therapy to neck; 10) endotracheal tube intubation within past 2 months;
11) diagnosis of vocal cord paralysis; 12) diagnosis of active granulomatous disease (laryngeal
or pulmonary, including sarcoid, Wegener’s, tuberculosis, histoplasmosis, blastomycosis) re-
quiring systemic therapy; and 13) suspicion of laryngeal neoplasm requiring biopsy for diag-
nosis
Interventions Rabeprazole 20mg twice-daily or placebo (identical appearance) for 2months. All also received
lifestyle modification instructions minimise acid reflux (avoidance of fatty meals, caffeine,
alcohol, smoking, and oral intake within 2 hours of lying down or bedtime, as well as the
addition of extra pillows to raise the head or bedpost blocks to elevate the head of the bed 6
inches)
Outcomes The primary outcome measures: change in total reflux symptom scores and proportion of
subjects noting significant global improvement. The reflux symptom scores were modification
of a previously validated GERD outcome questionnaire that included laryngo-pharyngeal
symptoms. The questionnaire included 9 items (heartburn, acid regurgitation, dysphagia,
globus, throat clearing, hoarseness, sinus drainage or phlegm, sore throat and dry cough).
Patients responded to frequency of symptoms (never, monthly, weekly, several times per week
or daily) and severity of symptoms (none, mild, moderate, severe, very severe), both scored 0
to 4 on a Likert scale. The total reflux symptom score included sum of frequency and severity
scores for all items
The secondary outcome measures were change in SF36, change in laryngeal grading of
videostrobolaryngoscopy, and changes in component reflux symptoms scores (frequency,
severity, “typical,” “laryngeal,” “pharyngeal” and individual symptoms). The component re-
flux symptom scores were defined as follows: frequency = sum of all reflux symptom frequency
scores; severity = sum of all reflux symptom severity scores; “typical” = sum of frequency
and severity scores for symptoms of heartburn and acid regurgitation; “laryngeal” = sum of
frequency and severity scores for symptoms of hoarseness, dry cough and throat clearing; and
“pharyngeal” = sum of frequency and severity scores for symptoms of throat clearing, globus
sensation and phlegm
The tertiary outcome measures were changes in frequency of lifestyle factors related to reflux
derived from the lifestyle questionnaire. The lifestyle questionnaire included9 items (smoking,
alcohol use, caffeine use, head of bed elevation with blocks, use of 2 pillows to raise head,
oral intake within 2 hours of bedtime, oral intake within 2 hours of lying down, antacid use
and histamine-2 receptor blocker use). Response choices included: never, monthly, weekly,
several times per week, and daily (0 to 4 Likert scale)
Notes Cough reported separately in paper. Authors contacted for further data
Risk of bias
Item Authors’ judgement Description
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Adequate sequence generation? Yes Randomisation by computer generated ran-
dom number table
Allocation concealment? Yes Sealed envelopes concealed randomisation
process from study investigators
Blinding?
Clinical cure/failure
Yes Placebo-controlled study, identical appear-
ance
Blinding?
Cough frequency or score
Yes Placebo-controlled study, identical appear-
ance
Free of other bias? Unclear Completion rate in 71.4%. Although sup-
ported by pharmaceutical industry, negative
study published
Vaezi 2006
Methods Multicentre, randomised, placebo-controlled, parallel-group trial that compared
twice-daily esomeprazole 40 mg with placebo for 16 weeks in adults with suspected chronic
laryngeal symptoms and signs from GOR (but those with significant GI manifestations of
GOR were excluded - see exclusion criteria)
Screening laryngoscopy and screening period were performed. Eligible patients then under-
went a 7- to 14-day screening period without treatment, during which they completed a daily
diary card on which they assessed each of 5 symptoms (throat clearing, cough, globus, sore
throat and hoarseness) over the past 24 hours on a 7-point Likert scale (0 = none to 6 =
very severe). At the end of this period, patients each identified their single most bothersome
symptom as the primary symptom. Patients eligible for randomisation must have completed
at least 80% of diary entries, had a cumulative primary symptom score of >= 9, and had >=
3 days with moderately severe symptoms (>= 3 points) over any 7 consecutive days of the 7
to 14 days
Participants randomised in a 2:1 ratio (esomeprazole:placebo) at each centre by blocks of 6
After randomisation and before receipt of study medication, patients had for ambulatory
pharyngoesophageal pH monitoring (APEM). Patients who refused APEM were allowed to
participate. APEM consisted of 2-catheter, 3-probe 24-hour study with probe placement in
the hypopharynx, proximal oesophagus and distal oesophagus. APEMwas assessed by a single,
independent investigator at a central laboratory, blinded to patient-identifying data
Patients used daily diary card used to assess symptoms each day throughout the 16-week trial.
At weeks 0, 4, 8, 12 and 16, the investigator assessed the same symptoms that the patients
assessed in their diary cards using a 4-point Likert scale (0 = none to 3 = severe). At the final
visit, the investigator also provided an overall evaluation of improvement
Allocation method not described. Compliance monitored by pill counting. Analysis was by
intention-to-treat not relevant. Total of 17 (11.7%) withdrawals
Quality score: B, A, A, B
Participants 146 participants randomised but 1 dropped out prior to any Rx (number screened not given)
. Patients enrolled from 7 US centres. Esomeprazole group (n = 95): mean age (SD) = 51.5
(15.2), 48 males and 47 females. Placebo group (n = 50): mean age (SD) = 50.5 (14.5), 23
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males and 27 females
Inclusion criteria: aged > 18 years and had one or more of the following symptoms for 3
or more consecutive months before screening: throat clearing, cough, globus, sore throat or
hoarseness; and laryngoscopic signs consistent with reflux (assessed by a panel via consensus)
Exclusion: clinically significant conditions that might, in the judgment of the investigator,
put the patient at risk, influence the results, affect the patient’s ability to participate in the
study, or necessitate surgery during the study. Patients who had experienced moderate-to-
severe heartburn 3 or more days per week over a 3-month period before screening; history
of respiratory or gastro-intestinal malignancy; radiation therapy to the head and neck, lung,
or gastrointestinal tract; gastroesophageal surgery; chronic sinusitis or rhinitis in the last
year; an allergic cause of laryngitis; an acute traumatic event near the larynx in the last year;
tracheostomy or other significant laryngeal or tracheal surgery; and substance or alcohol
abuse in the past year; other malignancy (except superficial basal cell carcinoma) within the
previous 5 years; presence of an infectious cause of laryngitis in the past 3 months; need for
continuous therapywithin 1week of randomisation with diazepam, phenytoin,mephenytoin,
warfarin, anticholinergics, antineoplastics, prostaglandin analogues, H2-receptor antagonists,
steroids (inhaled, oral, or intravenous), promotility drugs, and sucralfate; use of tobacco
products in the past year, any PPI in the last 2 weeks, theophylline, or any other investigational
compound or participation in another investigational drug study in the past 30 days; and any
contraindication to esomeprazole, such as known or suspected allergy or sensitivity to any
PPI; or pregnancy and lactating women
Interventions Esomeprazole 40 mg twice-daily or placebo (identical appearance) for 16 weeks
Outcomes Patients used daily diary card used to assess symptoms each day throughout the 16-week trial.
At weeks 0, 4, 8, 12 and 16, the investigator assessed the same symptoms that the patients
assessed in their diary cards using a 4-point Likert scale (0 = none to 3 = severe). At the final
visit, the investigator also provided an overall evaluation of improvement for each symptom
as follows: 0 = resolved, 1 = improved, 2 = same, 3 = worse
Laryngoscopic scoring performed at week 8 and 16
The primary outcome was % patients who had resolution of the primary symptom according
to patient diary card assessment at the final visit. Symptom resolution was defined as a primary
symptom severity score of 0 (none) during the last 7 days of the study, but allowing a score
of 1 (minimal severity) for up to 3 days
Secondary efficacy variables included relief of the primary symptom (by patient ),% symptom-
free days and % of symptom-free patients, symptom severity change from baseline, and the
investigator’s assessment of symptom-free patients. Relief of the primary symptomwas defined
as a greater than 50% reduction from baseline in the primary symptom score during the final
week
Notes Authors provided additional cough specific data
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not described
Allocation concealment? Unclear Information not available
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Blinding?
Clinical cure/failure
Yes Placebo-controlled study, identical appear-
ance
Blinding?
Cough frequency or score
Yes Placebo-controlled study, identical appear-
ance
Free of other bias? Yes Additional data provided by authors. Al-
though supported by pharmaceutical com-
pany, this negative studywas published.Good
follow-up rate
Vanderhoof 2003
Methods Multi-centre, randomised, double-blind, parallel study comparing a pre-thickened formula
with placebo in infants with regurgitant reflux
Parents of infants kept diary cards for 2 days and if eligible randomised. After 1 week, infants
were reviewed and commenced on pharmacological intervention (ranitidine after day 7/8 and
cisapride after day 14/15). Further follow up until day 35/36
Randomisation well described based on site but allocation method not described
Compliance monitoring done
Drop outs (n = 12, 10.9% of those randomised. Drop outs included in some analysis but not
described as treatment failures. Analysis by intention-to-treat not possible
Quality score: B, A, A, B
Participants 110 infants randomised (number screened not given) from 6 North American paediatric
centres. 7 drop outs and of remaining 103, mean age of 55 (27males, 28 females) intervention
group was 61 days (SD 4) and that of control group (26 males, 23 females) was 58 days (SD
4)
Inclusion: >= 5 regurgitations per day for 2 baseline days, age 14 to 120 days, gestational age
> 37 weeks, birth weight >= 2.5 kg, maternal age >= 18 years
Exclusion: congenital abnormalities interfering with normal feeding or causing repeated re-
gurgitation. Fever, infectious illness, clinical diagnosis of milk or soy protein allergy, compli-
cated GORD (oesophagitis, haematemesis, recurrent respiratory symptoms, failure to thrive),
previous treatment with thickened formula, or treatment with prokinetic medications 5 days
before start of study
Interventions A pre-thickened formula (Enfamil AR) with placebo for 35/36 days, with equal access to
additional pharmacological intervention
Outcomes 1. Regurgitation frequency, regurgitation volume, as documented on daily diary sheets for
the first week and then 2 days/week subsequently
2. Percentage feeds followed by choke/gag/cough
3. Trouble sleeping
4. Adverse events
Measured at week 1 and end of participation.
Notes Authors replied butwere unable to provide informationon cough alone as an outcomemeasure
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomisationdone per site butmethodused
not described
Allocation concealment? Unclear Information not available
Blinding?
Clinical cure/failure
Yes Placebo-controlled study, identical appear-
ance
Blinding?
Cough frequency or score
Unclear Not applicable for this study
Free of other bias? Unclear Insufficient data
Wo 2006
Methods Single centre, double-blinded, randomised, placebo-controlled trial that compared once daily
pantoprazole with placebo for 12 weeks in adults
Protocol was 2-week run-in, 12-week randomised treatment, and4-week off-treatment follow-
up periods. During the run-in period, subjects filled out weekly diaries. Subjects were seenmid
protocol. Naso-pharyngoscopy, oesophageal manometry and triple sensor pH monitoring
performed before Rx. Naso-pharyngoscopy, laryngoscopy and triple sensor pH monitoring
performed repeated on end of week 12. Diaries collected till 4 weeks post-Rx
Randomisation method and allocation method clearly described
High quality score: B, A, A, A
Study was financially supported by a pharmaceutical research grant
Participants 42 of 51 who had pHmonitoring qualified for study. Of these 42 adults, 39 were randomised
and all completed study
Pantoprazole group: n = 20 (7 males, 13 female), mean age = 39 years (range 23 to 59)
Placebo group: n = 19 (6 males, 13 female), mean age = 37 years (range 23 to 61)
Subjects were recruited from otolaryngology clinics at University of Louisville or through
newspaper advertisements
Inclusion criteria: subjects with themain complaint of hoarseness, sore throat, throat burning/
pain, throat clearing, voice loss, cough, excessive throat mucus, globus, or choking for > 3
days per week in the past 2 months. The diagnosis of LPR was confirmed by laryngeal exam
and a positive pH test of the hypopharynx or distal oesophagus (defined as total number of
hypopharyngeal reflux episodes >= 3 or distal oesophageal total time pH < 4 was >= 4.2%)
Exclusion criteria: previous treatment of LPR or GORD, known gastroparesis, connective
tissue disorder, previous endoscopic or surgical antireflux procedure, or gastric surgery. Also
those with vocal cord ulcer, vocal cord granuloma, or laryngeal malignancy seen on naso-
pharyngoscopic examination were excluded
Interventions Pantoprazole (40 mg once daily) or placebo for 12 weeks
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Wo 2006 (Continued)
Outcomes Symptom assessment: weekly diaries of visual analogue scales (0: none to 20: severe) for
6 laryngeal symptoms: globus, cough, sore throat, hoarseness, throat clearing and excessive
throat mucus. A total laryngeal symptom score (0 to 120) was defined as the sum of the
laryngeal symptoms. A similar visual analogue scale (0 to 20) was obtained for daytime and
night-time heartburn
Nasopharyngoscopy: reflux finding score (RFS) (higher = worse)
Notes -
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation assignment generated by
third party in blocks of 4 with sequential
numbering
Allocation concealment? Unclear Insufficient details to be certain if allocation
concealment occurred
Blinding?
Clinical cure/failure
Yes Placebo-controlled study, identical appear-
ance
Blinding?
Cough frequency or score
Yes Cough not measured but placebo-controlled
study, identical appearance
Free of other bias? Unclear Study was financially supported by a pharma-
ceutical research grant
ACE: angiotensin-converting enzyme; AE: adverse event; APEM: ambulatory pharyngoesophageal pH monitoring; AR: anti-reflux;
bd: twice-daily; COPD: chronic obstructive pulmonary disease; EKG: Electrocardiography ; ENT: ear, nose and throat; GI: gas-
trointestinal; GOR: gastroesophageal reflux; GORD: gastroesophageal reflux disease; LPR: laryngo-pharyngeal reflux; PND: post-
nasal drip; PPI: proton pump inhibitor; QID: four times a day; QT: a measure of the time between the start of the Q wave and the
end of the T wave in the heart’s electrical cycle; RFS: reflux finding score; SD: standard deviation; VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ahmad 2004 Non-RCT. Prospective follow up study of 303 adults with otolaryngeal manifestations of GORD. 86% had
cough and choking events presumed secondary to GORD (diagnosed on gastroscopy) were treated with antire-
flux therapy (PPI’s in 90%, ranitidine in 3%, Gaviscon in 11%). Complete response to therapy occurred in 25.
7%, no response in 23.1% and the rest had variable response. Adverse events not mentioned
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Allen 1998 Non-RCT. Prospective follow-up study of 195 adults with GORD (diagnosed objectively by combination
of gastroscopy, pH-metry, manometry) treated with Nissen fundoplication. Cough was primary reason for
surgery in 42 (21.5%) patients. Cough scores significant reduced post-surgery - 51% were cough-free and 31%
improved. Cough scores correlated to dysphagia score (r = 0.233, P = 0.004) but did not relate to scores for
heartburn, pain or regurgitation. Adverse events not mentioned
Allen 2002 Non-RCT. Prospective study on predictors for response of cough to laparoscopic fundoplication in 354 adults
(subgroup of total 603 fundoplication). Cough was eliminated in 54% of the 81% (287) followed up and
improved in further 31%. Strongest predictor for response of cough was preoperative cough score (r = 0.62).
Change in cough score on and off PPI, i.e. positive response to PPI (r = 0.296) was a weak predictor. Timescale
of response of PPI was not provided. Those with positive Bernstein test were more likely (P = 0.024) to respond
but predictive value not given. Adverse events not reported
Allen 2004 Non-RCT. Follow up of 209 with respiratory symptoms, mainly cough who underwent laparoscopic Nissen
fundoplication. 81% were followed at 6 months, 73% at 2 years, and 60% at 5 years. Cough improved in 83%
at 6 months, 74% at 2 years, and 71% at 5 years
Baldi 2006 Placebo not used. RCT comparing 30 mg bd of lansoprazole to 30 mg daily for 12 weeks. Authors suggest a
positive response at 4 weeks of PPI is an effective criteria for assessing response to PPI treatment
Baldi 2006a Non-RCT. Observational prospective study
Belafsky 2008 Retrospective study on LPR
Birk 2009 Non-controlled study involving 81 adults. Registry study aimed to evaluate Plicator procedure safety and efficacy
among GORD patients treated in routine clinical practice at multiple academic and non-academic centres. 57%
of patients had chronic cough. No significant reduction in coughing (or wheezing) post-surgery. Significant
reduction in GOR symptoms (heartburn and regurgitation) plus “extra-esophageal symptom of hoarseness”
Brouwer 2003 Non-RCT. Prospective study of 29 adults with GORD (diagnosed on gastroscopy) and respiratory symptoms
including cough (n = 19) following laparoscopic Nissen fundoplication. 14 months follow up; 3 required
conversion to open procedure, 4 with major complications. Cough (assessed by subjective score) reported to
resolve completely in 81% and improved in 13%. pH-metry findings in those with respiratory symptoms similar
to those with gastrointestinal symptoms
Chandra 2007 Review paper. No additional references identified
Chen 2000 Non-RCT. Retrospective and prospective study of 90 adults undergoing laparoscopic Nissen fundoplication,
97%with typical GI symptoms, 56% with concurrent non-GI symptoms including cough in 17%. Post-surgery
patients with non-GI symptoms improved in 54% but reflux symptoms in 95%. New symptoms of flatulence,
belching, dysphagia, chest and abdominal pain were reported but not measured. Surgical complications not
mentioned
Coron 2007 Review paper. One additional paper identified from references
Dalby-Payne 2003 Meta-analysis of cisapride for treatment of GORD in children. Cough was not an outcome measure in meta-
analysis
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DeMeester 1990 Non-RCT. Prospective study evaluating the effect of fundoplication in 17 adults with chronic/persistent res-
piratory symptoms (including cough) and GORD inpatients with or without chest radiograph abnormality.
Surgery was not beneficial only on those whose respiratory symptoms occurred pre reflux event. Those whose
respiratory symptoms occurred during or within 3 minutes following or were unrelated to reflux episodes and
had pre surgical normal motility were more likely to benefit
Dore 2007 Non-placebo-controlled RCT. Study used different PPIs (rabeprazole, pantoprazole, esomeprazole and lanso-
prazole) and placebo was not used
Duffy 2003 Non-RCT. Prospective study of 148 adults with GORD (diagnosed on gastroscopy, pH-metry or manometry)
undergoing laparoscopicNissen fundoplication.Of these 31%had cough pre-surgery.ModifiedGastrointestinal
Quality of Life Index used and no cough-specific scores utilised. Improved QOL post-surgery reported, surgical
complications not reported
Ekstrom 2000 Non-RCT. Prospective study evaluating the effect of fundoplication on 24 patients with severe GORD) and
concomitant asthma (n = 13) or chronic cough (n = 11). In non-asthmatic patients, daytime cough reduced by
47% and night cough by 80% 12 months after surgery
El Hennawi 2004 Non-RCT. 64 of 80 adults treated with ’anti-reflux Rx’. Before and after Rx effect described
Eubanks 2001 Non-RCT. Before and after PPI study for 3 months relating symptoms of cough, hoarseness and throat clearing
with proximal pH-metry in 14 adults, 7 of whom had cough. 5 of the 7 who improved with PPI had reduction
of > 70% of pharyngeal acid reflux i.e. 2 of 7 improved without significant reduction. PPI well tolerated, no
side effects reported
Farrell 2001 Prospective non-RCT. Symptoms measured pre and post-fundoplication (at 6 weeks) in 324 adults of which
67 had cough. Post-surgery, cough resolved in 67%, those with atypical symptoms of GORD were more likely
to have had less severe pH-metry indices than those with classical GORD symptoms
Fock 2008 Consensus guidelines. No additional references identified
Fraser 2000 Prospective non-RCT. Symptoms measured pre and post-PPI treatment (20 mg daily and if no response by 3
months increased to 40 mg daily) in 87 adults (25 had cough as primary symptom). After 6 weeks, 52% had
good response (undefined)
Gatta 2007 Meta-analysis assessing the effectiveness of medical or surgical therapy for reflux disease in adult patients
with laryngeal or pharyngeal symptoms presumed to be due to gastro-oesophageal reflux disease The authors
concluded that “Therapy with a high-dose proton pump inhibitor is nomore effective than placebo in producing
symptomatic improvement or resolution of laryngo-pharyngeal symptoms”
Gilger 2008 Study to evaluate safety, tolerability and symptom improvement with once-daily esomeprazole in children with
endoscopically proven gastroesophageal reflux disease (GERD). “Extra-oesophageal symptom” including cough
were reported in study but study excluded as placebo was not used
Greason 2002 Retrospective non-RCT in adults with primary respiratory symptoms. Most had abnormal pulmonary function
test
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Grill 1985 Non-RCT. Effect of domperidone (0.3 to 0.6 mg/kg/dose qid) on symptoms and oesophageal and gastric
motility in 15 infants (6 boys, mean age 7.9months), with moderate to severe GORD and upper gastrointestinal
motility disturbances. Vomiting, “spitting” and coughing improved significantly after 6 weeks therapy
Habermann 1999 Non-RCT. 6-week PPI (pantoprazole) used in 29 adults with ’laryngeal’ disorders presumed secondary to
GORD with symptoms including cough. Follow up at 6 weeks at end of treatment and at 3 months while off
therapy. Significant change in symptoms of heartburn, hoarseness, sore throat and dyspnoea but no significant
reduction in cough reporting at 6 weeks
Habermann 2002 Non-RCT. Prospective study of 14 adults patients with pharyngoesophageal gastric acid reflux (symptoms
include cough) receiving pantoprazole, 40 mg daily for 6 weeks. Significant improvement was observed in all
patients at 6 weeks, in 71% of the patients the 24-hour pH-metry indicated reflux
Hui 2000 Retrospective non-RCT - 30 adults with cough and GORD. 60% had symptoms resolve post-fundoplication
assessed at 6 to 36 months. Those without pre-operative nausea were more likely to have resolution of cough
Hunter 1996 Non-RCT. Review of 300 adults post-laparoscopic fundoplication (252 Nissen and 48 Toupet) for gastroe-
sophageal reflux refractory to medical therapy or requiring daily omeprazole or high-dose H2 antagonists. 64%
had atypical gastroesophageal reflux symptoms (including cough, asthma, hoarseness, chest pain) pre surgery.
Minor complications occurred in 6% and major complications in 2%. Atypical reflux symptoms were elimi-
nated or improved in 87% and no better in 13%
Irwin 1993 Non-RCT. Determination of characteristics of 12 adults with cough and GORD (diagnosed on disappearance
or marked improvement or treated with high protein, low fat, anti reflux diet). 75% of cohort had otherwise
silent GORD and pH-metry sensitive in 92% but positive Bernstein and Baker tests unhelpful
Irwin 2002 Non-RCT. Report on 8 adults said to have medication resistant GORD (objective diagnosis) and cough, 4
of whom had previous fundoplication. All had surgery or repeat fundoplication and cough scores reduced
postoperatively (median of 41 days). One year post fundoplication/repeat fundoplication, although median
cough scores of group were still significantly lower than immediate post-surgery, cough scores increased in 5
patients. Surgical complications not mentioned
Issing 2004 Non-RCT. 22 adults with chronic cough, globus pharyngeus, hoarseness or dysphonia (from ENT clinics)
treated with esomeprazole. After 8 weeks, 95% were symptom-free
Katzka 1996 Non-RCT. Prospective study of 14 adults with persistent symptoms (typical GI and atypical-asthma, cough,
hoarseness, throat burning or undetermined chest pain) despite standard PPI therapy (omeprazole 20 mg bd)
. Of the 6 with atypical symptoms studied, increased dose of omeprazole (20 mg qid) controlled reflux but
did not control atypical symptoms and pH-metry showed poor correlation between symptoms and acid reflux
(defined as > 50% association of symptoms with pH < 4 within 5 minutes)
Leeder 2002 Non-RCT. Prospective study on effect of laparoscopic fundoplication in 14 adults objective evidence of GORD
(without oesophagitis on endoscopy or pH-metry). Patients grouped into typical GI (heartburn, volume reflux,
vomiting or regurgitation) or atypical (cough, chest pain, bloating, belching, or choking). 3 of the 7 (43%) in
atypical symptom group had poor outcome post-surgery. 2 of these patients had cough but the effect of these
2 patients were not explicitly reported
Monini 2006 Non-placebo-controlled trial. All with laryngeal symptoms clinically graded as having GORD were given PPI
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Murray 2006 Non-RCT. Study described the outcome of patients with cough and paradoxical vocal fold movement disorder
treated with respiratory retraining therapy and management of laryngopharyngeal reflux
Novitsky 2002 Non-RCT. Prospective study on effect of fundoplication in 21 adults with chronic cough and GORD and were
unresponsive to PPIs and other medical therapy. Fundoplication was laparoscopic in 18 and open in 3. Cough
improved in 86% of which 62% had complete resolution of cough. No major perioperative complications
occurred
Omari 2006 RCT on effect of baclofen on physiological parameters of GOR with no clinical correlates measured as an
outcome, as reported by correspondence to corresponding author
Oridate 2008 Non-RCT. Observational study on 45 patients with laryngopharyngeal and oesophageal symptoms receiving
continuous proton-pump inhibitor for up to 6 months
Poe 2003 Non-RCT. Prospective study on 56 adults with chronic cough presumed related to GORD (clinical diagnosis).
Patients treated with PPI and if no response, metoclopramide or cisapride added. In 86% cough eliminated or
markedly improved after 4 weeks
Songur 2008 Non-RCT examining effect of PPI in adults with symptomatic cough and GORD diagnosed using scintigraphy
Swoger 2006 Prospective, controlled, non-randomised trial of 25 adults with LPR (of which 30% to 31% had chronic cough)
to fundoplication versus no fundoplication. No difference found between groups at 1 year, despite technical
success (increased lower oesophageal sphincter pressure and normalised oesophageal acid) in the fundoplication
group
Thoman 2002 Non-RCT. Retrospective study on effect of laparoscopic fundoplication 37 adults with cough and GORD.
Complete resolution of cough occurred in 64% with 10% reported improvement. Patients with cough and
GORD were more likely to have dysphagia post-surgery
Tibbling 1993 Non-RCT. Comparison of adults (mixed respiratory and non-respiratory disease) with GORD treated with
omeprazole (n = 89) and fundoplication (n = 199). Omeprazole (mean 50 days) did not significantly relieve
cough (34% pre and 28% post), but patients who had fundoplication and crural repair showed a highly
significant reduction of cough (34% pre and 7% post)
Tibbling 1995 Similar data set to 1993 paper
van Zanten 2006 RCT on 224 adults with functional dyspepsia using esomeprazole versus placebo. Cough was not listed amongst
the symptoms examined
Waring 1995 Non-RCT. Prospective study evaluating the effect of anti-reflux therapy (omeprazole 20 to 40 mg/day in 6 and
fundoplication in 21) in 27 adults with GORD and chronic cough or hoarseness. 80% improved including 36%
who became asymptomatic. Improvement of cough was more likely in those whose heartburn was eliminated.
No features of dual pH-metry could predict responders versus non- responders
Wo 1997 Non-RCT. Prospective study of 22 adults with posterior laryngitis (4 of whom the major symptom was cough)
treated with 40 mg qid of omeprazole for 8 weeks. Symptom score for cough significantly reduced by 8 weeks
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Wright 2003 Non-RCT. Prospective study on effect of laparoscopic fundoplication in 145 adults with hiatus hernia and
symptoms suggestive of GORD and laryngopharyngeal reflux. 55% had abnormal pH-metry. 41% of cohort
had cough pre-surgery of which 92% reported improvement. 5 (1.4%) had significant complications (2nd
surgery for bleeding, oesophageal perforation, severe odynophagia required in 3 and pulmonary embolus in 2)
Xinias 2003 Open placebo-controlled but non-randomised trial using modified milk for GORD in 56 infants. After 4 weeks
of therapy, there was no change in cough scores although significant reduction in reflux index, vomiting and
regurgitation episodes was found in treatment arm compared to placebo arm
Yang 2006 Non-RCT. Patients with chronic cough treated with 8 weeks of PPI
bd: twice-daily; ENT: ear, nose and throat; GI: gastrointestinal; GORD: gastroesophageal reflux disease; LPR: laryngo-pharyngeal
reflux; PPI: proton pump inhibitor; QID: four times a day; QOL: quality of life; RCT: randomised controlled trial; Rx: treatment
Characteristics of studies awaiting assessment [ordered by study ID]
Morice 2008
Methods RCT on proscriptive or standard anti-reflux advice with brief dietary weight loss intervention
Participants Obese adults with presumed cough associated with reflux
Interventions Dietary
Outcomes Cough QOL
Notes -
QOL: quality of life; RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Thickened versus unthickened feeds (infants)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Subjects cured (of cough) at end
of study
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Cough frequency 1 Coughs/hr (Fixed, 95% CI) Totals not selected
Comparison 2. PPI versus placebo (children)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Coughing (% days/week) 1 162 Mean Difference (IV, Fixed, 95% CI) 8.6 [-2.85, 20.05]
2 Clinical failures (still coughing at
end of trial or reporting period)
1 119 Odds Ratio (M-H, Fixed, 95% CI) 1.61 [0.57, 4.55]
3 Treatment-emergent serious
adverse events
1 162 Odds Ratio (M-H, Fixed, 95% CI) 5.56 [1.18, 26.25]
Comparison 3. PPI versus placebo (> 18 years)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failures (still coughing at
end of trial or reporting period)
4 191 Odds Ratio (M-H, Random, 95% CI) 0.46 [0.19, 1.15]
1.1 Medical clinics based
enrolment
2 38 Odds Ratio (M-H, Random, 95% CI) 0.17 [0.02, 1.73]
1.2 Otolaryngology based
enrolment
2 153 Odds Ratio (M-H, Random, 95% CI) 0.56 [0.21, 1.49]
2 Mean cough score at
end of trial (1st arm
cross-over/parallel-group trials)
4 109 Std. Mean Difference (IV, Fixed, 95% CI) -0.38 [-0.77, 0.00]
2.1 Medical clinic based
enrolments
1 21 Std. Mean Difference (IV, Fixed, 95% CI) -0.86 [-1.77, 0.05]
2.2 Otolaryngology based
enrolments
3 88 Std. Mean Difference (IV, Fixed, 95% CI) -0.28 [-0.70, 0.14]
3 Change in cough scores
(end-beginning of
intervention - 1st arm
cross-over/parallel-group trials)
6 161 Std. Mean Difference (IV, Fixed, 95% CI) -0.39 [-0.71, -0.08]
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3.1 Studies using omeprazole 2 51 Std. Mean Difference (IV, Fixed, 95% CI) -0.71 [-1.29, -0.14]
3.2 Studies using other PPI
(lansoprazole, pantoprazole,
rabeprazole)
4 110 Std. Mean Difference (IV, Fixed, 95% CI) -0.26 [-0.64, 0.12]
4 Change in cough scores
(cross-over studies; standardised
scale)
2 SD units (Fixed, 95% CI) -0.41 [-0.75, -0.07]
4.1 Sub-category 2 SD units (Fixed, 95% CI) -0.41 [-0.75, -0.07]
5 Absolute cough scores (cross-over
studies, standardised scale)
2 SD units (Fixed, 95% CI) -0.29 [-0.62, 0.04]
6 Change in cough score after
4 weeks treatment (1st arm
cross-over/parallel-group trials)
2 51 Std. Mean Difference (IV, Fixed, 95% CI) -0.51 [-1.08, 0.06]
7 Difference in cough scores at
week 8 - week 4 (1st arm
cross-over/parallel-group trials)
2 51 Std. Mean Difference (IV, Fixed, 95% CI) -0.44 [-1.04, 0.16]
Analysis 1.1. Comparison 1 Thickened versus unthickened feeds (infants), Outcome 1 Subjects cured (of
cough) at end of study.
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 1 Thickened versus unthickened feeds (infants)
Outcome: 1 Subjects cured (of cough) at end of study
Study or subgroup Thickened feeds Unthickened feeds Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chao 2007 0/5 2/4 0.09 [ 0.00, 2.68 ]
0.01 0.1 1 10 100
Favours thickened feeds Favours control
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Analysis 1.2. Comparison 1 Thickened versus unthickened feeds (infants), Outcome 2 Cough frequency.
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 1 Thickened versus unthickened feeds (infants)
Outcome: 2 Cough frequency
Study or subgroup Coughs/hr (SE) Coughs/hr Coughs/hr
IV,Fixed,95% CI IV,Fixed,95% CI
Orenstein 1992 1.1 (0.89) 1.10 [ -0.64, 2.84 ]
-4 -2 0 2 4
Thickened better Unthickened better
Analysis 2.1. Comparison 2 PPI versus placebo (children), Outcome 1 Coughing (% days/week).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 2 PPI versus placebo (children)
Outcome: 1 Coughing (% days/week)
Study or subgroup PPI Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Orenstein 2009 81 0 (42.9) 81 -8.6 (30.43) 100.0 % 8.60 [ -2.85, 20.05 ]
Total (95% CI) 81 81 100.0 % 8.60 [ -2.85, 20.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours PPI Favours placebo
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Analysis 2.2. Comparison 2 PPI versus placebo (children), Outcome 2 Clinical failures (still coughing at end
of trial or reporting period).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 2 PPI versus placebo (children)
Outcome: 2 Clinical failures (still coughing at end of trial or reporting period)
Study or subgroup PPI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Orenstein 2009 54/61 48/58 100.0 % 1.61 [ 0.57, 4.55 ]
Total (95% CI) 61 58 100.0 % 1.61 [ 0.57, 4.55 ]
Total events: 54 (PPI), 48 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours experimental Favours control
Analysis 2.3. Comparison 2 PPI versus placebo (children), Outcome 3 Treatment-emergent serious adverse
events.
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 2 PPI versus placebo (children)
Outcome: 3 Treatment-emergent serious adverse events
Study or subgroup PPI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Orenstein 2009 10/81 2/81 100.0 % 5.56 [ 1.18, 26.25 ]
Total (95% CI) 81 81 100.0 % 5.56 [ 1.18, 26.25 ]
Total events: 10 (PPI), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours experimental Favours control
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Analysis 3.1. Comparison 3 PPI versus placebo (> 18 years), Outcome 1 Clinical failures (still coughing at
end of trial or reporting period).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 3 PPI versus placebo (> 18 years)
Outcome: 1 Clinical failures (still coughing at end of trial or reporting period)
Study or subgroup PPI Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medical clinics based enrolment
Kiljander 2000 7/9 12/12 8.2 % 0.12 [ 0.01, 2.85 ]
Ours 1999 7/8 9/9 7.4 % 0.26 [ 0.01, 7.43 ]
Subtotal (95% CI) 17 21 15.6 % 0.17 [ 0.02, 1.73 ]
Total events: 14 (PPI), 21 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
2 Otolaryngology based enrolment
Eherer 2003 2/5 4/6 13.5 % 0.33 [ 0.03, 3.93 ]
Vaezi 2006 79/94 43/48 70.9 % 0.61 [ 0.21, 1.80 ]
Subtotal (95% CI) 99 54 84.4 % 0.56 [ 0.21, 1.49 ]
Total events: 81 (PPI), 47 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Total (95% CI) 116 75 100.0 % 0.46 [ 0.19, 1.15 ]
Total events: 95 (PPI), 68 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.097)
0.005 0.1 1 10 200
PPI better Placebo better
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Analysis 3.2. Comparison 3 PPI versus placebo (> 18 years), Outcome 2 Mean cough score at end of trial
(1st arm cross-over/parallel-group trials).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 3 PPI versus placebo (> 18 years)
Outcome: 2 Mean cough score at end of trial (1st arm cross-over/parallel-group trials)
Study or subgroup PPI Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Medical clinic based enrolments
Kiljander 2000 9 5.89 (5.01) 12 9.91 (4.1) 17.8 % -0.86 [ -1.77, 0.05 ]
Subtotal (95% CI) 9 12 17.8 % -0.86 [ -1.77, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.065)
2 Otolaryngology based enrolments
Eherer 2003 5 0.4 (0.55) 6 1.5 (1.64) 9.3 % -0.79 [ -2.04, 0.47 ]
Noordzij 2001 15 243.3 (346.62) 15 328.2 (473.67) 28.6 % -0.20 [ -0.92, 0.52 ]
Pawar 2007 21 0.29 (0.64) 26 0.5 (1.1) 44.3 % -0.22 [ -0.80, 0.35 ]
Subtotal (95% CI) 41 47 82.2 % -0.28 [ -0.70, 0.14 ]
Heterogeneity: Chi2 = 0.71, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Total (95% CI) 50 59 100.0 % -0.38 [ -0.77, 0.00 ]
Heterogeneity: Chi2 = 1.98, df = 3 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Chi2 = 1.27, df = 1 (P = 0.26), I2 =21%
-4 -2 0 2 4
Favours PPI Favours Placebo
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Analysis 3.3. Comparison 3 PPI versus placebo (> 18 years), Outcome 3 Change in cough scores (end-
beginning of intervention - 1st arm cross-over/parallel-group trials).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 3 PPI versus placebo (> 18 years)
Outcome: 3 Change in cough scores (end-beginning of intervention - 1st arm cross-over/parallel-group trials)
Study or subgroup PPI Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Studies using omeprazole
Kiljander 2000 9 -4.55 (5.18) 12 1.33 (5.18) 11.4 % -1.09 [ -2.03, -0.15 ]
Noordzij 2001 15 -112.9 (165.68) 15 -20 (207.16) 19.0 % -0.48 [ -1.21, 0.25 ]
Subtotal (95% CI) 24 27 30.4 % -0.71 [ -1.29, -0.14 ]
Heterogeneity: Chi2 = 1.01, df = 1 (P = 0.32); I2 =1%
Test for overall effect: Z = 2.42 (P = 0.015)
2 Studies using other PPI (lansoprazole, pantoprazole, rabeprazole)
Eherer 2003 5 -1.4 (2.7) 6 -2.66 (3.14) 6.9 % 0.39 [ -0.81, 1.59 ]
Havas 1999 8 -0.9 (3.37) 7 -0.86 (3.33) 9.8 % -0.01 [ -1.03, 1.00 ]
Pawar 2007 21 -0.52 (1.123) 26 0.08 (0.775) 28.9 % -0.62 [ -1.21, -0.03 ]
Steward 2004 18 -1.2 (2.48) 19 -0.9 (3.02) 24.1 % -0.11 [ -0.75, 0.54 ]
Subtotal (95% CI) 52 58 69.6 % -0.26 [ -0.64, 0.12 ]
Heterogeneity: Chi2 = 3.01, df = 3 (P = 0.39); I2 =0%
Test for overall effect: Z = 1.33 (P = 0.19)
Total (95% CI) 76 85 100.0 % -0.39 [ -0.71, -0.08 ]
Heterogeneity: Chi2 = 5.68, df = 5 (P = 0.34); I2 =12%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 1.66, df = 1 (P = 0.20), I2 =40%
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Analysis 3.4. Comparison 3 PPI versus placebo (> 18 years), Outcome 4 Change in cough scores (cross-over
studies; standardised scale).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 3 PPI versus placebo (> 18 years)
Outcome: 4 Change in cough scores (cross-over studies; standardised scale)
Study or subgroup SD units (SE) SD units Weight SD units
IV,Fixed,95% CI IV,Fixed,95% CI
1 Sub-category
Eherer 2003 -0.34 (0.277) 38.7 % -0.34 [ -0.88, 0.20 ]
Kiljander 2000 -0.45 (0.22) 61.3 % -0.45 [ -0.88, -0.02 ]
Total (95% CI) 100.0 % -0.41 [ -0.75, -0.07 ]
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours PPI Favours placebo
Analysis 3.5. Comparison 3 PPI versus placebo (> 18 years), Outcome 5 Absolute cough scores (cross-over
studies, standardised scale).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 3 PPI versus placebo (> 18 years)
Outcome: 5 Absolute cough scores (cross-over studies, standardised scale)
Study or subgroup SD units (SE) SD units Weight SD units
IV,Fixed,95% CI IV,Fixed,95% CI
Eherer 2003 -0.161 (0.27) 39.9 % -0.16 [ -0.69, 0.37 ]
Kiljander 2000 -0.375 (0.22) 60.1 % -0.38 [ -0.81, 0.06 ]
Total (95% CI) 100.0 % -0.29 [ -0.62, 0.04 ]
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 PPI versus placebo (> 18 years), Outcome 6 Change in cough score after 4
weeks treatment (1st arm cross-over/parallel-group trials).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 3 PPI versus placebo (> 18 years)
Outcome: 6 Change in cough score after 4 weeks treatment (1st arm cross-over/parallel-group trials)
Study or subgroup PPI Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kiljander 2000 9 -1.78 (4.47) 12 -1.58 (3.78) 43.1 % -0.05 [ -0.91, 0.82 ]
Noordzij 2001 15 -166.8 (197.17) 15 9.4 (199.98) 56.9 % -0.86 [ -1.62, -0.11 ]
Total (95% CI) 24 27 100.0 % -0.51 [ -1.08, 0.06 ]
Heterogeneity: Chi2 = 1.95, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 PPI versus placebo (> 18 years), Outcome 7 Difference in cough scores at week
8 - week 4 (1st arm cross-over/parallel-group trials).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 3 PPI versus placebo (> 18 years)
Outcome: 7 Difference in cough scores at week 8 - week 4 (1st arm cross-over/parallel-group trials)
Study or subgroup PPI Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kiljander 2000 9 -4.67 (2.17) 12 2.16 (3.9) 30.1 % -2.00 [ -3.09, -0.90 ]
Noordzij 2001 15 53.9 (161.51) 15 10.6 (206.83) 69.9 % 0.23 [ -0.49, 0.95 ]
Total (95% CI) 24 27 100.0 % -0.44 [ -1.04, 0.16 ]
Heterogeneity: Chi2 = 11.09, df = 1 (P = 0.00087); I2 =91%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours PPI Favours Placebo
A P P E N D I C E S
Appendix 1. Archive of search results (all years to April 2007)
The Airways Group specialised register/search identified 763 potentially relevant titles in the original search in 2004. After assessing
the abstracts, 84 papers were obtained for considered for inclusion into review. The main reason for non-eligibility of studies for review
criteria was the non-controlled, non-randomised nature of the respective studies (see table ’Characteristics of excluded studies’). One
controlled but non-randomised study was also excluded (Xinias 2003). Eleven studies were included in the original version of the
review (see ’Characteristics of included studies’), and all but one (Vanderhoof 2003) were single centre studies. The multicentre study
(Vanderhoof 2003) was also the only study supported by commercial interest then. In the 2005 update a further 11 articles were
retrieved; one study was included (El Serag 2001) and the rest were excluded, with two described in the excluded table (El Hennawi
2004; Issing 2004). Following the 2006 search update, eight papers were retrieved. One RCT in adults (Vaezi 2006) was included
and another RCT was excluded (Baldi 2006) as a placebo was not used. The excluded study compared two doses of lansoprazole for
adults with chronic cough (Baldi 2006). Following the 2007 search update, 407 abstracts were reviewed, 12 papers were retrieved; none
fulfilled eligibility criteria. One study that was excluded but should be highlighted was that of a controlled (but non-randomised) trial
on fundoplication for laryngopharyngeal reflux (LPR) of which 30% to 31% of the subjects had chronic cough, the 2nd or 3rd most
common symptom (Swoger 2006). Swoger 2006 described no difference between groups at one year, despite technical success of the
fundoplication. A systematic review on the efficacy of PPIs for LPR was also excluded (Gatta 2007). The paper (Gatta 2007) however
revealed a relevant study that was not found in previous searches; this study (Steward 2004) is now included in this update.
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Appendix 2. CENTRAL search strategy
#1 MeSH descriptor Gastroesophageal Reflux explode all trees in MeSH products
#2 ((gastro-oesophageal next reflux) or (gastroesophageal next reflux) or (gastro-esophageal next reflux) or reflux or ger or gerd or acid
or esophagus or oesophagus)
#3 MeSH descriptor Esophagus explode all trees in MeSH products
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Cough explode all trees in MeSH products
#6 MeSH descriptor Bronchitis explode all trees in MeSH products
#7 cough*
#8 bronchiti*
#9 (#5 OR #6 OR #7 OR #8)
#10 (#4 AND #9)
Appendix 3. MEDLINE search strategy
1. exp COUGH/
2. exp Bronchitis/
3. (cough$ or bronchit$).mp.
4. 1 or 2 or 3
5. exp GASTROESOPHAGEAL REFLUX/
6. exp Esophagus/
7. (gastro-oesophageal reflux or gastroesophageal reflux or gastro-esophageal reflux or reflux or ger or gerd or acid or esophagus or
oesophagus).mp.
8. 5 or 6 or 7
9. 4 and 8
(Combined with the RCT filter as described in ’About the Airways Group’ on T he Cochrane Library)
Appendix 4. EMBASE search strategy
1. exp Coughing/
2. exp Bronchitis/
3. (cough$ or bronchit$).mp.
4. 1 or 2 or 3
5. exp Gastroesophageal Reflux/
6. exp esophagus/
7. (gastro-oesophageal reflux or gastroesophageal reflux or gastro-esophageal reflux or reflux or ger or gerd or acid or esophagus or
oesophagus).mp.
8. 5 or 6 or 7
9. 4 and 8
(Combined with the RCT filter as described in ’About the Airways Group’ in T he Cochrane Library).
WH A T ’ S N E W
Last assessed as up-to-date: 9 June 2010.
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Date Event Description
15 July 2010 New search has been performed New literature search run.
15 July 2010 New citation required and conclusions have changed We updated the risk of bias using the Cochrane ’Risk of
bias’ tool rather than the Jadad scoring system. We added
one new relatively large study. The conclusions changed for
children as proton pump inhibitors (PPI) were shown not to
be efficacious against cough in childrenwith gastroesophageal
reflux disease (GORD) symptoms, and there were increased
serious adverse events
H I S T O R Y
Protocol first published: Issue 3, 2004
Review first published: Issue 2, 2005
Date Event Description
23 April 2010 Amended New search performed. Studies added.
24 April 2009 New search has been performed Literature search re-run; nonew studieswere identified.
11 April 2008 New search has been performed Literature search re-run; four new studies were identi-
fied which met the eligibility criteria of the review. The
conclusions were not altered on the basis of the new
trial evidence
5 April 2008 Amended Converted to new review format.
1 August 2007 New citation required but conclusions have not
changed
One new study met the entry criteria of the review
(Steward 2004). This study was identified from a sys-
tematic review on laryngopharyngeal reflux and cough
(Gatta 2007). It contributed data to a secondary out-
come (change in cough scores at end of intervention),
but did not alter the conclusions of the review
6 September 2006 New citation required but conclusions have not
changed
One new study met the entry criteria of the review
(Vaezi 2006). This study contributed data to the pri-
mary outcome (still coughing at end of trial), but did
not alter the conclusions of the review
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have used the Cochrane risk of bias tool in this update. We included a new sensitivity analysis for cross-over and parallel studies.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Age Factors; Chronic Disease; Cough [etiology; ∗therapy]; Gastroesophageal Reflux [complications; ∗therapy]; Histamine H2 Antag-
onists [therapeutic use]; Proton Pump Inhibitors [therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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